Round 1 (Collection date March 2020)

ApplicantsCountry

McKay, Dave M. (Principal applicant)

Aniridia Network

United Kingdom

van Heyningen, Veronica

Institute of Ophthalmology, University College London

United Kingdom

Sánchez de Vega, Rosa

Aniridia Europe

Norway/Spain

Moosajee, Mariya

Institute of Ophthalmology, University College London

United Kingdom

Bylė, Irma

Association “AniridijaLT”

Lithuania

Lima Cunha, Dulce

Institute of Ophthalmology, University College London

United Kingdom

Damante, Giuseppe

Dept. Medicine, University of Udine

Italy

Hall, Hildegard Nikki

MRC Institute of Genetics and Molecular Medicine, University of Edinburgh/ Princess Alexandra Eye Pavilion, Edinburgh

United Kingdom

Grupcheva, Christina

Dept. Ophthalmology and Visual Science, Varna Medical University

Bulgaria

Tsoneva, Elena

Association Aniridia Bulgaria

Bulgaria

Abstract
This event enables sharing of specialist knowledge about the rare genetic eye condition aniridia. Its goal is to develop better understanding to tackle sight loss and other effects of to aniridia. Professionals such as: ophthalmologists, researchers, vision scientists, and geneticists will gather with people who have aniridia and their relatives, to upskill each other. Aniridia is visual impairment present at birth. Most people with aniridia have all or part of their irises (the coloured rings in the eyes) missing. Other parts of the eye are typically under-developed. Other conditions often lead to further sight loss. Aniridia is usually caused by an abnormality in a gene called PAX6. It also controls brain and pancreas functions. So patients may also have disturbed sleep and predispositions to obesity or diabetes. It can occur as part of more significant condition known as WAGR/11p Deletion Syndrome. Understanding aniridia is challenging, due to the scattered patient population, its highly variable impact and complications of linked conditions. This event innovatively addresses this by bringing all the stakeholders together for 3 days. Researchers and clinicians will discuss their latest work and experience of the disease, with contributions from patients. New approaches to clinical management, drug development, and stem cell therapy will be presented. There will also be tours of the laboratories at UCL Institute of Ophthalmology. Patients and relative have the unique chance to get a free 30 minute consultation with the world’s top aniridia experts at Moorfields Eye Hospital.

Applicants

Country

Schermer, Bernhard (Principal applicant)

Department II of Internal Medicine, Nephrolab,

University Hospital of Cologne

Germany

Firat-Karalar, Elif Nu,

Dept. of Molecular Biology and Genetics, Koç University

Turkey

Čajánek, Lukáš

Faculty of Medicine, Dept. of Histology and Embryology, Masaryk University

Czech Republic

Wloga, Dorota

Nencki Institute of Experimental Biology, Polish Academy of Sciences

Poland

Harris, Tess

Ciliopathy Alliance

United Kingdom

Mill, Pleasantine

MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh

United Kingdom

Blacque, Oliver

Conway Institute; School of Biomolecular and

Biomedical Science, University College Dublin

Ireland

Jurisch Yaksi, Nathalie

Kavli Institute for Systems Neuroscience, Norwegian University of Science and Technology

Norway

Meunier, Alice

Institut de Biologie de l’Ecole Normale Supérieure, CNRS

France

Abstract
Cilia are tiny, antennae-like cell organelles that can be found on almost all cells of the human body. Research has revealed, that a growing number of genetic diseases result from defects in cilia collectively termed the ‘ciliopathies’. Some cilia are motile and involved in moving either liquids or cells within the body, whilst other cilia are immotile and transmit key signals from outside to the cell’s interior. Since cilia occur within virtually all tissues, the spectrum of cilia-associated diseases is very broad, affecting the kidneys, lungs, brain, eyes and many more. The ciliopathies represent a spectrum of ~40 overlapping syndromes caused by mutations in nearly 200 genes. Whilst often very rare individually, collectively the ciliopathies are thought to affect 1:1000 births. In October, basic researchers and clinicians from all over the world will meet in Cologne at “Cilia2020”. As the largest cilia conference, it uniquely integrates patients and their representatives in the program with the aim of promoting bidirectional interactions between scientists and those impacted by ciliopathies. In 2020, we aim to expand this meeting to countries typically underrepresented in any international research networks and to enlarge the community. Our “Cilia2020 – Interconnect” satellite events aim to sustainably enhance diversity of the cilia/ciliopathy community within and around Europe. This will accelerate gene discovery and improve understanding of disease mechanisms, as well as facilitating development of much needed therapies for ciliopathies.

Applicants

Country

Sireau, Nicolas (Principal applicant)

The AKU Society

United Kingdom

Santucci, Annalisa

Biotechnology Chemistry & Pharmacy, Università degli Studi di Siena

Italy

Lakshminarayan, Ranganath

Clinical Biochemistry & Metabolic Medicine, Royal Liverpool Hospital, Liverpool University Hospitals

United Kingdom

Zatkova, Andrea

Biomedical Research Centre, Institute for Clinical and Translational Research, Slovak Academy of Sciences, Bratislava

Slovak Republic

De Kock, Joery,

Dept Toxicology, Vrije Universiteit Brussel (VUB), Faculty of Medicine and Pharmacy

Belgium

Imrich, Richard

Biomedical Research Centre, Institute for Clinical and Translational Research, Slovak Academy of Sciences, Bratislava

Slovak Republic

Kujawa, Mariusz

Radiology, Institution Medical University of Gdansk

Poland

Gallagher, James

Dept  Musculoskeletal Biology, University of Liverpool

United Kingdom

Abstract
Alkaptonuria, also known as AKU or Black Bone Disease, is an extremely rare genetic condition, which can cause significant damage to the bones, cartilage and tissues of those affected. AKU normally only affects one in every 250,000 people worldwide. It causes a build-up of a substance called homogentisic acid (HGA), which binds to cartilage and bone and turns tissues black, in a process called ochronosis. This causes severe early onset osteoarthritis. The nature of the disease leads to severe disability and long-term pain.
The AKU Scientific Conference will facilitate the sharing of knowledge about the condition among AKU world experts and aspiring scientists wishing to excel in AKU research in the future. It will focus on next steps in research following the recently ended DevelopAKUre clinical trials, a future gene therapy, an upcoming children’s study and a co-therapy for patients to take alongside the vital drug nitisinone – a drug which improves symptoms and signs of AKU. This conference will be key for pushing forward the next exciting stages of AKU research as we now have a successful drug that is on its way to be licensed, and we are looking to advance research to cure AKU.
Our conference will be the first steps towards the final stage of the AKU mission, to find a cure for this debilitating disease.

Applicants

Country

Kedar, Amir (Principal applicant)

The Israeli Wiskott Aldrich Syndrome Association

Israel

Thrasher, Adrian

Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, London

United Kingdom

Albert, Michael

Pediatric Hematology/Oncology, Dr. von Hauner University Children’s Hospital, LMU, Munich

Germany

Villa, Anna

Sr TIGET, IRCCS Ospedale San Raffaele, Milan

Italy

Abstract
The third international symposium for researchers and clinicians on Wiskott Aldrich Syndrome is being held in London UK and offers access to the latest research and analysis related to this rare disease. The participants will gain valuable insights into innovative perspectives in both basic and clinical research. The scientific programme will draw together experts from around the world to discuss breakthroughs in basic research, advances in clinical practice, novel therapeutic approaches and new insights into stem-cell and cellular therapies. This unique networking event is ideal forum to share knowledge, connect with colleagues and grow professional network. The goals of this meeting are:

  • Expanding WAS/XLT and WASp research.
  • Bridging the gap between basic and clinical research to speed up applications.
  • Foster collaboration among researchers.
  • Attract young researchers to focus on WAS/XLT and WASp.

Our three keynote lectures present the most recent knowledge in the research and clinical field of WAS. Prof. David Rawlings will talk about “Lessons learned regarding immune tolerance and progress towards new therapies for WAS”, Prof. Anna Villa will shed light on « Platelets defects in Wiskott-Aldrich Syndrome » and Prof. Michael Albert will discuss about « HSCT for WAS – What have we learned in 50 years and what promises does the future hold? ». As in our previous events, unpublished data regarding WAS and WASp research will be presented and discuss among participants. The data presented and the different topics discussed in this event are rarely accessible elsewhere

Applicants

Country

Scarpa, Maurizio ( (Principal applicant)

Regional Coordinating Centre for metabolic diseases, Azienda Sanitaria Universitaria Friuli, Udine

Italy

Jansen, Marleen

Netherlands National Institute for Public Health and the Environment (RIVM)

The Netherlands

Cornel, Martina

Clinical Genetics and Amsterdam Public Health Research Institute, Amsterdam University Medical Center

The Netherlands

Tangeraas, Trine

Dept. of Paediatric and Adolescent Medicine, OUH Riskhospitalet

Norway

Kozich, Viktor

Dept of Paediatric and Adolescent Medicine, Charles University-1st Faculty of Medicine and General University Hospital, Prague

Czech Republic

 

Bonham, Jim

Clinical Chemistry, Sheffield Children’s NHS Foundation Trust

United Kingdom

Hedley, Victoria

John Walton Muscular Dystrophy Research Centre, Newcastle University

United Kingdom

Baumgartner, Matthias

Division of Metabolism, University Children’s Hospital Zurich – Eleonore Foundation

Switzerland

Abstract
There are big differences between European countries when it comes to newborn screening (NBS). Taking into consideration the overall needs and priorities regarding health conditions and system resources, there is room for a feasible improvement on NBS programmes in EU by means of a shared consensus document (roadmap). We consider it crucial to initiate a broad discussion involving the whole spectrum of stakeholders participating in debates about NBS such as representatives of scientific organisations, patient representatives, MetabERN and other stakeholders. We therefore organize two meetings in 2020 to drive this topic forward to deepen collaboration between stakeholders: a brainstorming session in April organized by MetabERN and a meeting under the EJP-NSS, which will integrate wider stakeholder perspectives to advance the topic of NBS. This meeting will be organised back-to-back with the conference of the International Society for Newborn Screening (ISNS). It will build upon past discussions and first steps from Member States under the EU Committee of Experts on Rare Diseases and reignite discussions on areas for potential European-level collaboration. The final result will be a consensus paper with steps toward identifying potential barriers and finding common grounds for NBS, involving pre-post born management, follow up of the affected child, family assistance and discuss technical discussion regarding criteria for the expansion of NBS . The outcome of this process will be a roadmap for policy-makers, the scientific community and advocacy organisations.

Round 2 (Collection date September 2020)

Applicants

Country

Petersen, Claus (Principal applicant)

Pediatric Surgery, Hannover Medical School

Germany

Davenport, Mark

Pediatric Surgery, Kings College Hospital, London

United Kingdom

Verkade, Hendrik Jan

Pediatric gastroenterology and hepatology and nutrition, The Beatrix Children’s Hospital of the University Medical  Center Groningen

The Netherlands

Socha, Piotr

Gastroenterology, Hepatology, Pediatrics and Nutritional Disorders, The Childrens’ Memorial Health Institute, Warsaw

Poland

Fischler, Björn

Pediatric hepatology, Karolinska University Hospital, Stockholm

Sweden

Dezsöfi, Anta

First Dept of Pediatrics, Semmelweis University, Budapest

Hungary

Wildhaber, Barbara

Pediatric surgery, University Hospitals of Geneva

Switzerland

Madadi-Sanjiani, Omid

Pediatric Surger, Hannover Medical School

Germany

Pakarinen, Mikko Petteri

Dept. Pediatric Surgery, Children’s Hospital, Helsinki University Hospital, University of Helsinki

Finland

Samyn, Marianne

Paediatric Liver, GI and Nutrition Centre, King’s College Hospital NHS Foundation Trust, London

United Kingdom

Abstract
The BARD-Bruges-2021 congress is the 2nd International and Interdisciplinary event about biliary atresia and related diseases. The core issues of the program are six controversial topics: neonatal cholestasis (diagnostic algorithm); biliary atresia (surgery/ adjuvant therapy/transition); cholangitis (definition/therapy); choledochal malformations (diagnostic algorithm, timing and technique ofsurgery, long-term follow-up) portal hypertension (diagnostics/shunting) and pediatric liver surgery (incl. liver transplantation). The faculty members have already built multidisciplinary pre-congress working groups in order to develop broad-based consensus. The aim is to formulate, using Delphic principles, six reliable algorithms and best procedure protocols before the meeting. During the meeting we will debate the proposals and achieve some sorely-needed consensus and expert-led guidelines, which will be submitted to relevant peer-reviewed journals. In Bruges, we desire synergisms with other ERN-rare-liver disease groups and will actively involve patients´ organisations. Additional topics are the role of screening programs (biliary atresia) and transition of adolescent patients into adult medicine.The meeting in Bruges is structured as a continuation of the BARD-Berlin-2014 congress. For further information click at www.bard-online.com.

Applicants

Country

Scheiner, Bernhard (Principal applicant)

Dept. Internal Medicine III, Division of  Gastroenterology and Hepatology, Medical University of Vienna

Austria

Rautou, Pierre-Emmanuel

Dept. Hepatology, Inserm – Université de Paris

France

Garcia-Pagan, Juan Carlos

Liver Unit, Hospital Clinic de Barcelona, University of Barcelona

Spain

Lisman, Johannes Antonius (Ton)

Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen

The Netherlands

Procopet, Bogdan

3rd Medical Clinic, University of Medicine and Pharmacy „Iuliu Hatieganu” Cluj-Napoca

Romania

Abstract
The term “vascular liver diseases” comprises several rare diseases such as the idiopathic non-cirrhotic portal hypertension, the porto-sinusoidal vascular disease, the Budd-Chiari-Syndrome, the Rendu-Osler-Weber syndrome, the sinusoidal obstruction syndrome as well as splanchnic vein thromboses. According to a recent publication by the European Association for the Study of the Liver (EASL) one of these diseases affects around 1 in 10000 persons. Proper knowledge on the natural course of these diseases as well as adequate management are important as these entities often affect young and otherwise healthy individuals and may cause significant morbidity and mortality. However, diagnosis and treatment initiation are commonly delayed which also prompted the Vascular Liver Disease Group (VALDIG) of the EASL to define a new entity named “porto-sinusoidal vascular disease” in 2019 to facilitate diagnosis and stipulate research in this area. Unfortunately, patients with idiopathic non-cirrhotic portal hypertension / porto-sinusoidal vascular disease are still commonly misdiagnosed as having liver cirrhosis which may not only cause improper treatment but also stigmatization. One of the difficulties in diagnosis and treatment of these entities, is the need for a strong cooperation between different specialists such as hepatologists, pathologists as well as (interventional) radiologists. Therefore, the aim of this networking meeting is to improve knowledge on these diseases and to stipulate multidisciplinary, international research in order to improve the management of our patients.

Applicants

Country

Alberch, Jordi (Principal applicant)

Dept. Biomedical Sciences, University of Barcelona

Spain

Danek, Adrian

Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich

Germany

Sibon, Ody

Dept. Cell Biology, University of Groningen

The Netherlands

Hermann, Andreas,

Translational Neurodegeneration Section “Albrecht Kossel”, Dept Neurology, University Rostock

Germany

Zoladek, Teresa

Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw

Poland

Miltenberger, Gabriel

Instituto de Medicina Molecular, University of Lisbon

Portugal

De Franceschi, Lucia

Dept. Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata

Italy

Irvine, Ginger

Advocacy for Neuroacanthocytosis Patients

United Kingdom

Velayos-Baeza, Antonio

Dept. Physiology, Anatomy and Genetics, The Wellcome Trust Centre for Human Genetics, University of Oxford

United Kingdom

Abstract
Neuroacanthocytosis syndromes (NA) are a group of rare, but devastating, neurodegenerative disorders, with Chorea Acanthocytosis as the “core” disease of this family. To date there are no treatments that can halt or slowdown the progression of these diseases. Since these are ultra-rare disease, there is very little or no support of industry and other public and private agencies is rare. Therefore, it is very important for these patients to have a strong NA community bringing together basic and clinical neuroscientists, neurologists and patients worldwide to address new discoveries in these diseases. This international community was successfully established 20 years ago. Thus, the aim of the 10th International Meeting on Neuroacanthocytosis Syndromes is to continue with this scientific / social platform that has been very useful to lead scientific approaches and the guidelines of patients’ healthcare for almost two decades. The setting of the meeting will encourage interactions, exchange of ideas and networking opportunities among all participants. PhD students and young researches will have the opportunity to present and discuss their work during the meeting. It is very relevant that patients, caregivers and patient’s associations are present in this meeting together with scientists and physicians. Thus, the meeting program schedules mixed sessions where the next steps and action points (scientific /social) are discussed to establish synergies in our quest to advance knowledge and practice. We must work all together to give some hope to the patients and their families.

Applicants

Country

Coppola, Antonietta (Principal applicant)

Neuroscience, Odontostomatology and Reproductive Sciences, Federico II University of Naples

Italy

Depienne, Christel

Institut für Humangenetik, University Hospital Essen

Germany

Van Rootselaar, Anne-Fleur

Dept. Neurology, Amsterdam UMC/Academic Medical Center; University of Amsterdam

The Netherlands

Striano, Pasquale

Dept. of Neurosciences, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genoa, G.Gaslini Institute

Italy

Licchetta, Laura

Dept. Biomedical and Neuromotor Sciences, IRCCS Istituto delle Scienze Neurologiche di Bologna, University of Bologna

Italy

Van den Maagdenberg, Arn

Depts. Human Genetics & Neurology, Leiden University Medical Center

The Netherlands

Tijssen, Marina

Dept. Neurology, Expertise centre Movement Disorders Groningen, University of Groningen

The Netherlands

Brancati, Francesco

Dept. Life, Health and Environmental Sciences, University of l’Aquila

Italy

Baykan Betül

Depts. Neurology and Clinical Neurophysiology, Istanbul University Faculty of Medicine

Turkey

Canafoglia, Laura

Epileptology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan

Italy

Abstract
Familial Adult Myoclonic Epilepsy (FAME) is an autosomal dominant rare genetic condition, characterized by cortical tremor, myoclonus and generalized tonic-clonic seizures. FAME is considered a slowly progressive neurodegenerative condition.
Recently the genetic cause has been identified as a complex intronic pentameric expansion followed by a pentameric insertion affecting different genes: SAMD12 for families linked to chr8q24(FAME1), STARD7 for families linked to chr2p11.2-q11(FAME2), MARCHF6 for families linked to chr5p15.31-p15 (FAME3), YEATS2 for families linked to chr3q26q28(FAME4). Although the proteins encoded by these genes have different functions and subcellular localizations, the pathogenic mechanism might be the same. Indeed the production of the proteins is not affected suggesting that the expansion itself could produce toxic RNA species. The neurophysiological and neuropathological findings point out the cerebellum as a key brain structure of the dysfunctions. Indeed the cortical hyperexcitability could result from the decreased cortical inhibition by the cerebellum through cerebello-thalamocortical projections. At this moment there is neither a resolving nor preventive treatment for FAME. Clinical management is based on antiepileptic medications that control seizures while having a limited effect on the myoclonus. Notably, some antiepileptic drugs are contraindicated or even deleterious in this condition. Elucidating the pathogenesis of this condition would provide further insight into a possible precision medicine approach.

Applicants

Country

Del Álamo, Marta (Principal applicant)

Clinical Operations, European Clinical Research Infrastructure Network, Paris

France

Lingor, Paul

Dept. of Neurology, Klinikum rechts der Isar der TU München

Germany

Bührer, Christoph

 Klinik für Neonatologie, Charité – Universitätsmedizin Berlin

Germany

Griese, Matthias

Division of Pediatric Pneumology, University Hospital Munich, Dr. von Hauner Children´s Hospital

Germany

Sireau, Nick

AKU Society

United Kingdom

Hivert, Virginie

Eurordis-Rare Diseases Europe

France

Palladini, Giovanni

Biotechnology Research Laboratories, Foundation “Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia

Italy

Fischer, Dirk

Neuropediatrics, University Children’s Hospital Basel

Switzerland

Demlová, Regina

Dept. Pharmacology, Masaryk University, Brno

Czech Republic

Sangiorgi, Luca

Dept. Rare skeletal disorders, Istituto Ortopedico Rizzoli, Bologna

Italy

Abstract
Drug development in RD have many challenges, as the lack of clinical research experts and the scarcity of patients. Multinational clinical trials are required to achieve sufficient recruitment but international collaboration in clinical trials is constrained by scientific, ethical, economical and regulatory considerations. Different sponsors may have different capacities to address these constraints leading to different collaborative patterns. Academic-led clinical trials face a high number of specific challenges, including lack of funding, inadequate infrastructures to plan and execute the trials or structured processes to facilitate academic collaborations, that results in difficulties to access the right partner assisting on the operational management. Academic-sponsored trials often focus on refining indications of available treatments and to optimize therapeutic strategies that do not have as much financial gain to the pharmaceutical industry, thus having their own additional specific significance. In recognition of the importance of supporting academic clinical research despite its many challenges, this workshop will gather investigators involved in rare-diseases academic-sponsored trials on drug repurposing and other RD clinical research stakeholders (clinical research infrastructures, RD supporting programs representatives, patient organizations) to identify systematic problems/challenges in the set-up of academic-sponsored international clinical trials and promote initiatives aiming to fill up the gaps (guidelines, recommendations, inventories of existing tools).

Round 3 (Collection date December 2020)

Applicants

Country

Zschocke, Johannes (Principal applicant)

Institute for Human Genetics, Medical University Innsbruck

Austria

Kapferer-Seebacher, Ines

Dept. Operative and Restorative Dentistry, Medical University Innsbruck

Austria

Gaboriaud, Christine

Institute for Structural Biology, Interdisciplinary Research Institute of Grenoble

France

Van Dijk, Fleur

North West Thames Regional Genetics Service, London North West Healthcare NHS Trust

United Kingdom

Malfait, Fransiska

Center for Medical Genetics, Ghent University and Ghent University Hospital

Belgium

Abstract
Ehlers-Danlos syndromes (EDS) are a heterogeneous group of connective tissue disorders. Apart from 3 common types (classical/vascular/hypermobile EDS) there are 10 rare types linked to 20 different disease genes. The pathogenesis of the rare EDS forms and the reasons for variable clinical presentations are only partly understood. Latest research suggests important links of the innate immune system with connective tissue homeostasis which is particularly relevant for the rare EDS types. This has also been the focus of an ANR-FWF funded Austrian-French joint project on the link between complement 1 and periodontal EDS. The planned networking event – planned as a hybrid meeting – will summarize current knowledge about the production, assembly and regulation of extracellular matrix components as well as their possible interaction with the immune system. Normal and abnormal cellular functions in the rare EDS types will be discussed also with regard to therapeutic options.
Aim is the strengthening and expansion of the rare EDS clinical and basic research networks with identification of the most pertinent research questions. The meeting combines state-of-the art research and overview presentations with reports from clinical cohort studies. It is linked to a patient-oriented virtual meeting in which the current knowledge on all rare EDS types is presented to an international audience including patients and non-specialist clinicians. This will be broadcast live with translation in 4 languages with support of the EDS Society, an international patient advocacy organization.

Applicants

Country

Viti, Federica (Principal applicant)

Institute of Biophysics, National Research Council, Genova

Italy

Ceccherini, Isabella

Lab. Genetics and Genomics of Rare Diseases, Istituto Giannina Gaslini, Genova

Italy

Vassalli, Massimo

James Watt School of Engineering, University of Glasgow

United Kingdom

Thapar Nikhil

Dept. Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London

United Kingdom

Molnar, Maria Judit

Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest

Hungary

Palmitelli, Alessandro

Associazione Poic e dintorni Onlus

Italy

Alves, Maria

Dept. Clinical Genetics, Erasmus University Medical Center

The Netherlands

Abstract
Visceral Myopathy (VSCM), a myogenic form of chronic intestinal pseudo-obstruction, is a rare severe genetic disease showing variable neonatal dysfunction in bladder and gut motility. It often provides an overall devastating clinical picture. The true incidence of VM remains largely unknown due to difficulties in diagnosis. Nevertheless, available data suggest that VM is very rare, showing an incidence of possibly <1 in 100,000. VSCM lacks effective strategies to diagnose, characterise and manage.
The creation of an International and multidisciplinary taskforce between clinicians, researchers and Patient Advocacy Organizations representatives is necessary to address major VSCM needs. A kick-off event is crucial to support the establishment of a long-lasting European initiative to focus on the many challenges posed by VSCM. The event will focus on state of the art, emerging approaches and futuristic visions related to VSCM, with special interest for: clinical diagnosis and patient management; genetics and onset molecular mechanisms; advanced models and methods to address VSCM diagnosis and therapy; therapeutic approaches and potential candidates for drug treatments; research-support framework. Expected outcomes of the event regard: 1. a clear assessment of the state of the art on VSCM; 2. the identification of the most pressing needs in the context of disease management; 3. the creation of scientific taskforces to address outstanding topics in research and clinic; 4. the coordination of European data and material sharing initiatives; 5. a future common fund-raising strategy.

Applicants

Country

Aibar Moreno, José Angel (Principal applicant)

Dravet Syndrome Foundation Spain

Spain

Cardenal Munoz, Elena

Dravet Syndrome Foundation Spain

Spain

Broccoli, Vania

Division of Neuroscience, San Raffaele Scientific Institute – CNR Neuroscience Institute, Milan

Italy

Rubinstein, Moran

Goldschleger Eye Research Institute. The Department of Fluman Molecular Genetics and Biochemistry, Tel Aviv University

Israel

Lignani, Gabriele

Dept. Clinical and Experimental Epilepsy, UCL, Queen Square Institute of Neurology, London

United Kingdom

Elernandez-Alcoceba, Ruben

CIMA, Gene Therapy Program, University of Navarra

Spain

Mantegazza, Massimo,

Institute of Molecular and Cellular Pharmacology, CNRS and University Cote d’Azur, Valbonne

France

Karda, Rajvinder

Institute for Women’s Health, University College London

United Kingdom

Hernando Llorente, Rodrigo

Dravet Syndrome Foundation Spain

United Kingdom

Abstract
Dravet syndrome (DS) is a rare disease whose symptoms start in the first year of life, with seizures triggered by fever followed by a drug-resistant epilepsy. It also causes severe cognitive, motor and speech delays, as well as behavioural problems. Due to the genetic nature of the disease, advanced therapies (AT) such as those based in gene or protein modification represent new hope in the search for an effective treatment for this pathology.
Dravet Syndrome Foundation Spain (FSD) and the Dravet Syndrome Advanced Therapies European Working Group (DS ATEWG), formed by top scientists in the field of AT for DS and related encephalopathies, organize the European Dravet Syndrome Advanced Therapies Meeting 2021 (EDSAT 2021), a 1-day satellite meeting to the Dravet Syndrome Conference 2021. This international networking event, held in Madrid (ES) on September 24, 2021, provides an excellent opportunity to meet friends and colleagues, foster new relationships and collaborations, and develop strategies for efficient and productive scientific outcomes.
Scientists will share first-hand information about their most recent advances in AT and DS research. In addition, attendees will learn from and discuss with guest industry regulatory and clinical experts in product and clinical development. Overall, EDSAT 2021 is an ideal platform for exchange, where students, early career scientists, leading investigators, policy makers, pharmaceutical industry and other sectors in healthcare converge and collaborate for the common goal of promoting DS research and patient access to AT.

Applicants

Country

Titulaer, Maarten Jan (Principal applicant)

Dept Neurology, Erasmus University Medical Center

The Netherlands

Massacesi, Luca

Dept Neurosciences Drugs and Child Health, Florence University

Italy

Gastaldi, Matteo

Neuroimmunology laboratory/Neuroncology and Neuroinflammation Unit, IRCCS Mondino Foundation, Pavia

Italy

Easton, Ava

The Encephalitis Society

United Kingdom

Graus, Francesc

Dept. Neuroimmunology, Institut Recerca Biomèdica August Pi i Sunyer, Barcelona

Spain

Erdag, Ece,

Dept. Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul

Turkey

Dalmau, Josep

Dept. Neuroimmunology, Institut Recerca Biomèdica August Pi i Sunyer, Barcelona

Spain

Honnorat, Jerome

Dept. Neuro-oncology, University Claude Bernard, Lyon

France

Leypoldt, Frank

Dept. Neurology and Inst. of Laboratory Medicine, University Hospital-Schleswig-Holstein & Kiel University

Germany

Tanasescu, Radu

Dept. Neurology, Nottingham University Hospitals, University of Nottingham

United Kingdom

Abstract
Autoimmune Encephalitis (AIE) are a group of severe, but treatable immune-mediated diseases of the brain. Although the frequency of each specific AIE is low, as a group these are less rare. As many types are only discovered over the last decade, it is increasingly recognized, but underdiagnosis is still likely. As AIE occur at all ages, admission is often long and consequences can be severe, it poses a high burden on the health care system. Recent diagnostic criteria for AIE have been proposed by an international, European-led team. This has improved clinical characterization and allowed earlier diagnosis and treatment. Early treatment is curative improving outcome, and preventing relapses. Due to the rarity of the separate AIE entities, randomized clinical trials are lacking. Expert opinion is based on case series. A task force (TF) of experts, endorsed by the European Academy of Neurology, is to create consensus on management of AIE. In extension to this guideline, the TF identified knowledge gaps.
In this conference, the TF is to be expanded to create a European network: TREAT AIE. Aims are standardization of data, sharing of databases, creating an European framework database, leading to fruitful research collaborations. This will lead to uniformity of cohort descriptions, enabling comparative research. Prospectively, this will enable randomized controlled trials. Altogether, this will improve diagnosis and treatment of patients with AIE in the whole of Europe. It will also reinforce European research at the front line in the field of rare neuroimmunological diseases.

Round 4 (Collection date March 2021)

Applicants

Country

Scarcelli, Vincenza (Principal applicant)

SCN8A Italia ODV

Italy

Fazeli, Walid

Dept Neuropediatrics, University Hospital Bonn

Germany

Aras Portilla, Luis Miguel

ApoyoDravet

Spain

Gardella, Elena

Danish Epilepsy Centre / University of Southern Denmark

Denmark

Clay, Benjamin

SCN8A UK and Ireland

United Kingdom

Abstract

The first ever European SCN8A & SCN2A Conference takes place at the University of Bonn (10th-11th September 2021) with a full virtual alternative.

SCN8A and SCN2A related diseases are extremely rare, likely under diagnosed, neurodevelopmental disorders caused by variants to the SCN2A / SCN8A genes. Outcomes vary, but the disorders often cause severe epilepsy, intellectual disability, autism, movement disorder and risk of sudden unexpected death in epilepsy. While sharing similarities with better known Dravet Syndrome (SCN1A), SCN8A/2A are different and can require different treatment. Improved awareness and early diagnosis are key.

SCN2A & SCN8A also have differences, but as rare sodium-channel disorders there is commonality of research and expertise. Despite being newly discovered disorders momentum is now building with various strands of SCN8A/2A research, growing patient registries, prospective specific medication trials, gene therapy research and natural history studies.

The SCN8A and SCN2A patient network is also growing with families forming groups in respective European nations, with groups connecting across Europe and beyond. This increasingly visible patient network offers helps researchers access and further aids the growth of the patient registries.

At this critical time, the conference brings together specialist clinicians, researchers and patient advocates. This intersection of data, expertise and research will enhance insight into genotype/phenotype relationships, enrich knowledge of optimum therapies, and stimulate ideas for new research streams.

Applicants

Country

Sabater, Lidia (Principal applicant)

Dept. Neuroimmunology, Fundacio Clinic per a la Recerca Biomedica (FCRB)

Spain

Gaig, Carles

Dept. Neurology. Multidisciplinary sleep disorder Unit, Hospital Clínic de Barcelona

Spain

Höftberger, Romana

Dept Neurology, Medical University of Vienna

Austria

Titulaer, Maarten Jan

Dept Neurology, Erasmus University Medical Center, Rotterdam

The Netherlands

Leypoldt, Frank

Dept. Neurology & Inst. of Laboratory Medicine University Hospital-Schleswig-Holstein & Kiel University

Germany

Dalmau, Josep

Dept Neuroimmunology, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona

Spain

Iranzo, Alejandro

Dept. Neurology. Multidisciplinary sleep disorder Unit, Hospital Clínic de Barcelona

Spain

Graus, Francesc

Dept Neuroimmunology, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona

Spain

Gelpí, Ellen

Dept Neurology, Medical University of Vienna

Austria

Marusič, Petr

Dept Neurology, Charles University and Motol University Hospital, Prague

Czech Republic

 

Abstract

The anti-IgLON5 disease is a rare neurological disease that can be life-threating. The patients are adults on their sixties and the main symptoms of the disease are sleep problems with apneas and gait imbalance. Other frequent symptoms are speech difficulties, breathing or swallowing problems, abnormal movements, dementia, muscular problems like cramps and weakness. At present we don’t know the cause of this disease or the mechanisms that are involved. As the disease is rare and was discovered only a few years ago there are a lot of things that are unknown. We believe that the disease begins when the human body’s defenses go wrong and attack normal parts of the brain. Patients with IgLON5 antibody disease slowly deteriorate and their symptoms can resemble those of a neurodegenerative disease such as Alzheimer’s, making the diagnosis difficult. In addition, the brains of patients with this disease at autopsies also resemble those of Alzheimer’s patients because we see that neurons are lost and there are abnormal accumulations of proteins. It is possible that the sooner patients are diagnosed and treated, the better they go and have a better prognosis. Our aim is to create a transnational consortium to study the disease and join the efforts of different centers in a collaborative way to exchange information about treatments and outcomes and also design experiments to know more about why and how this disease is produced.

Applicants

Country

Kocic, Maja (Principal applicant)

Lymphoma Patient Association LYPA

Serbia

Petrova, Pirinka

Bulgarian Lymphoma Association

Bulgaria

Vincek, Drazen

Croatian Leukaemia and Lymphoma Society

Croatia

 

Abstract

There are more than 80 subtypes of lymphomas that have very different biology making this a complex group of rare cancers.Despite that, lymphoma has more standard and, in particular, more emerging, novel treatments than most other types of cancer, patients with lymphoma in Europe do not all receive the same high standard of treatment and care. There are wide variations in how and when treatments reach patients. The Balkan region is among the poorest areas in Europe. Balkan countries continue to make slow progress in modernising their health systems. Moreover, intra-regional distinctions are clear: while EU members Bulgaria and Croatia have access to EU structural funds, Serbia has made more moderate progress and has generally lagged behind.

Patients with lymphoma, regardless of which country they belong to, need to have access to accurate information on their specific subtype, their treatment options, including clinical trials, and to be involved in the decision-making process when determining the course of their treatments.

The main goal of the event is to examine the extent of the disparities from a multidimensional patient perspective. Access to new treatments and to clinical trials in the fast-moving lymphoma field are obvious factors to examine, but patients are also disempowered through lack of information and support that can greatly affect their access to care and quality of life. Consequently, access to adequate care, including therapies, clinical trials, personal support and information, is the primary topic of our event.

Round 5 (Collection date June 2021)

Applicants

Country

Badnjarevic, Ivana (Principal applicant)

Lil’ Brave One (Hrabrisa)

Serbia

Opladen, Thomas

Div. Child Neurology and Metabolic Medicine, University Hospital Heidelberg

Germany

Stevanovic, Galina

Dept Neurology, Clinic for Neurology and Psychiatry for Children and Youth, Belgrade

Serbia

Garcia Cazorla, Angels

Neurometabolism unit, Hospital San Juan de Deu in Barcelona

Spain

Bertoldi, Mariarita

Dept Neuroscience, Biomedicine and Movement Sciences, University of Verona

Italy

Kulhanek, Jan

Dept Pediatrics and Inherited Metabolic Disorders, Charles University and General University Hospital, Prague

Czech Republic

Cinquemani, Claudio

SSADH-Defizit

Germany

Peñarrubia, Francisco

De Neu Asociación de Enfermedades de los Neurotransmisores

Spain

Yıldız, Yılmaz

Dept Pediatric Metabolism, Hacettepe University, Ankara

Turkey

Rossignoli, Giada

Dept Developmental Neurosciences, Molecular Neurosciences, UCL ZCR COS Institute of Child Health, London

 

United Kingdom

 

Abstract

Neurotransmitter diseases are a group of rare genetic diseases with neurometabolic implications and a wide spectrum of clinical presentations. The term “neurotransmitters” subsumes different types of chemical messengers enabling brain function through neuronal communication. In 2013, the “International Working Group on Neurotransmitter Related Disorders (iNTD)” was established to coordinate scientific and clinical efforts since each single expert centre involves a limited number of patients.

The general aim of the present Networking event is, for the first time, to bring together clinical scientists, basic researchers and patient advocacy groups to enable an interdisciplinary exchange, thus, to promote health for patients affected with rare neurotransmitter related disorders. The network strengthening will be carried out thanks to mixed sessions, involving all partners, discussing together on the scientific advancements of research and diagnostic tools as well as on novel cell models that pave the way to new disease treatments and medical protocols. The outputs will provide research advancements, iNTD network expansion to further medical centres and patients, and bring knowledge for all participants, due to the unprecedent opportunity to exchange scientific and clinical expertise conjugated to patient experience.

In addition, the network event will reduce variation between (underrepresented) countries, support Early Career Researchers and empower patients, wherever they live, to access the necessary expertise and services in a more global and shared perspective.

Round 6 (Collection date September 2021)

Applicants

Country

De Koning-Tijssen, Marina (Principal applicant)

Dept. Neurology, University Medical Centre Groningen

The Netherlands

Leuzzi, Vincenzo

Dept. Human Neuroscience, Sapienza University, Rome

Italy

Rubboli, Guido

Inst.Clinical Medicine, University of Copenhagen

Denmark

Anderson, David

Dept. Neurology, Queen Elizabeth, University Hospital,University of Glasgow

United Kingdom

Lehesjoki, Anna-Elina

Samfundet Folkhälsan i svenska Finland rf and University of Helsinki

Finland

Van Egmond, Martje

Dept. Neurology, University Medical Centre Groningen

The Netherlands

Galosi, Serena

Dept. Human Neuroscience, Sapienza University, Rome

Italy

De Koning, Tom

Dept. Pediatrics, Lund University

Sweden

Abstract
Progressive myoclonus ataxia (PMA) is a rare syndrome of the nervous system characterized by two different kinds of involuntary movements, namely myoclonus (unexpected muscle jerks) and ataxia (coordination difficulties). These abnormal movements with an onset in early childhood are in most patients accompanied by mild cognitive impairment and infrequent epilepsy. The disease course is progressive and can result in patients becoming wheelchair-bound in their second decade and, unfortunately, early death in their third or fourth decade. The cause of PMA mostly relies on a specific problem in the genes, which were only discovered recently. Currently, successful treatment of PMA is limited and mainly by means of anti-epileptic drugs. However, not all anti-epileptic drugs can be prescribed as some worsen the symptoms of PMA patients and do not satisfactorily suppress symptoms. This warrants the search for other treatment options. In a rare disease entity such as PMA, international collaboration is crucial. Therefore, we are organizing a face-to-face international networking event to bring together physicians, researchers, patient representatives, pharmacologists and policy makers involved in the field of PMA to  bundle forces and create new insights together. The aim is to translate these insights into new research projects where we will work towards working towards a more rational, more optimal treatment of PMA. The two-day networking event consists of various workshops and live discussions. It will take place in Groningen, the Netherlands, and it is planned in December 2022.

 

 

Applicants

Country

Ortigoza-Escobar, Juan Dario (Principal applicant)

Dept. Pediatric Neurology, Hospital Sant Joan de Deu, Barcelona

Spain

Panagiotakaki, Eleni

Dept Paediatric Clinical Epileptology, Sleep and Neurophysiology, University Hospital Lyon

France

Malenica, Maša

Child neurology and epileptology, UHC Sestre milosrdnice, Zagreb

Croatia

Arzimanoglou, Alexis

University Hospitals of Lyon and Hospital Sant Joan de Déu, Barcelona, Spain

France

Fons, Carmen

Dept. Pediatric Neurology, Hospital Sant Joan de Deu, Barcelona

Spain

Bibić, Irena

Croatian Dravet syndrome

Croatia

Silva, Susana

Spanish GNAO1 association

Spain

Tomassi, Massimiliano

Famiglie GNAO1 APS

Italy

Poncelin, Dominique

Association Française de l’Hémiplégie Alternante (A.F.H.A.)

France

 

Abstract
Pediatric rare neurological disorders are frequently unrecognized, resulting in a protracted delay in diagnosis and limited treatment options. Even when detected early, treatment remains mostly empirical, in part due to the limitations inherent in designing and conducting clinical trials: several of these disorders with similar clinical expressions are caused by a wide variety of affected genes, while therapy in one group of patients may not be applicable to all individuals with the same gene defect.
The primary goal of this networking event is to bring together clinicians and scientists from different EU and other countries, strongly involved in clinical and/or fundamental research in the fields of epilepsy and movement disorders. The event will examine the possibility of novel treatment approaches in light of recent developments in this field. Researchers will be offered the opportunity to construct new collaborations, debate on the development of precision medicine hypotheses and treatment trials to reach more patients across Europe. One of the workshop’s main draws is that it intends to address several of these uncommon neurological disorders concomitantly, encompassing both diagnostic and therapeutic issues. Bringing together senior and young academics, as well as patient advocacy organizations, will improve existing initiatives, stimulate new ones, and function as a catalyst for research in this sector. The event will be held in Barcelona, Spain during the 1st semester of 2022.

Applicants

Country

McLin, Valérie (Principal applicant)

Dept Pediatrics, Gynaecology and Obstetrics, University Hospitals Geneva, and University of Geneva

Switzerland

Franchi-Abella, Stéphanie

Dept. Pediatric Radiology, Hôpital Bicêtre

France

Guérin, Florent

Dept. Pediatric Surgery, Hôpital Bicêtre

France

Pop, Tudor

2nd Pediatric Clinic, University of Medicine and Pharmacy, Cluj-Napoca

Romania

Van der Doef, Hubert,

Lab. Medical Genetics, UMC Groningen

The Netherlands

Savale, Laurent

Dept. Respiratory Medicine, Hôpital Bicêtre

France

Plessier, Aurélie

Centre de référence des maladies vasculaires du foie, Hepatology unit, Hôpital Beaujon, Clichy

France

De Gottardi, Andrea

Servizio di Gastroenterologia e Epatologia, Ente Ospedaliero Cantonale, Lugano

Switzerland

Beghetti, Maurice

Dept Pediatrics, Gynaecology and Obstetrics, University Hospitals Geneva, and University of Geneva

Switzerland

Baiges, Anna

Dept. Hepatology, Hospital Clínic de Barcelona

Spain

 

Abstract
Congenital porto-systemic shunts (CPSS) are an anomaly of abdominal veins by which blood leaving the intestine bypassesthe liver. It is now understood that when the blood does not pass through the liver, such as in case of CPSS, severe complications can occur starting at a very young age. Although the prevalence of this rare malformation is not known, the following complications have been described both in children and adults: liver tumors, heart failure, vascular anomalies of the lung, developmental delay and more. Presently, it is not known which patients will develop complications. To this end, the International Registry for Congenital Portosystemic Shunts (IRCPSS) was created in 2016 with a view to achieve the following aims: i) understand who will develop complications, ii) identify the correct time and method to close the shunt(s), and iii) develop recommendations for the diagnosis, management and follow up of patients with this rare congenital malformation. To date 50 centers from 20 countries have pledged to join the IRCPSS. One of the idiosyncrasies of CPSS is the manifold presentations and therefore how awareness needs to span many medical specialties. Therefore, the aim of the proposed networking event to be held in Paris in March 2022, is to bring together current partners across all disciplines and other interested parties from Europe and the world to a) increase awareness and decrease time to diagnosis b) strengthen ties between partners to encourage ancillary projects and c) increase participation in the registry.

Applicants

Country

Verhoeven, Peter (Principal applicant)

Vasculitis International

The Netherlands

Power, Julie

Vasculitis Ireland Awareness

Ireland

Mills, John

Vasculitis UK

United Kingdom

Christofidou, Maria

The European Institute for Innovation Through Health Data (i-HD), Ghent University Hospital

Belgium

Durante, Eugenia

APACS – Associazione Pazienti Sindrome di Churg-Strauss

Italy

Hrušková, Zdenka

Dept. Nephrology, General University Hospital in Prague

Czech Republic

Vella, Mary

Arthritis and rheumatism Association

Malta

Anastasa, Zoi

Vasculitis UK

United Kingdom

 

Abstract
This first International Vasculitis Patient Conference is a satellite back-to-back event of the International Vasculitis and ANCA Symposium 2022. This patient conference will turn the COVID 19 restrictions into an advantage by providing an ideal networking opportunity for researchers and HCPs to hear the patient voice, and for patients to engage with research activities and shape the research agenda. It represents a unique transnational collaboration between Patient Advocacy Organizations (PAOs), Early Career Scientists (ECR’s), Established Researchers, and Health Care Professionals (HCP’s) in the field of Vasculitis. Team members represent many different countries including usually underrepresented EU member states like the Czech Republic and Malta. The team has the full support of organisations like the European Reference Network Rare Immunodeficiency, Autoinflammatory, Autoimmune disorders and Paediatric Rheumatology- ERN RITA, the scientific group European Vasculitis Society – EUVAS , the organising committee of the main conference and other senior scientists and clinicians in the field of vasculitis. During this patient conference we will broadcast live sessions where ECR’s and Patient Representatives discuss current insights in research progress from both a scientific and patient perspective. Senior researchers will be asked to contribute to these discussions. We will subtitle these sessions in multiple languages, and they will be available freely to all member states at a later date on the Vasculitis International website.

Round 7 (Collection date December 2021)

ApplicantsCountry

Wagner, Thomas (Principal applicant)

Dept. Frankfurter Referenzzentrum für Seltenen Erkrankungen (FRZSE), Universitätsklinikum Frankfurt

Germany

Humbert, Marc

Service de Pneumologie et soins Intensifs Respiratoire, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Université Paris-Saclay

France

Delcroix, Marion

Dept Pneumology, University Hospitals Leuven

Belgium

Torbicki, Adam

Dept. Pulmonary Circulation, Thromboembolic Disease and Cardiology Center of Postgraduate Medical Education, ECZ-Otwock

Poland

Hoeper, Marius

Dept Respiratory Medicine, Hannover Medical School

Germany

Kovacs, Gabor

Dept. Internal Medicine, Division of Pulmonology, Medical University of Graz

Austria

Godinas, Laurent

Dept. Respiratory Diseases, University Hospitals Leuven

Belgium

Abstract

In 2011, PHA Europe initiated a roundtable discussion with the involvement of all the stakeholders from the globe in the field of pulmonary hypertension, which resulted in the Call to Action on the Unmet needs of Patients with Pulmonary Hypertension in 2012.

Ten years have lapsed since the launch of this paper in the European Parliament, so it was high time to

  1. look back to assess the achievements and revisit the call to action to map out what is still ahead of us
  2. discuss which parts of the paper need to be re-drafted in light of the political and scientific developments since, and
  3. which fields are in need of more attention and allocation of added efforts and resources?

The planned networking event is the closing event of the re-assessment process of the call to action and the official re-launch of the revised paper in the European Parliament with the involvement of representatives from the patient associations and medical field, European level policy makers, representatives from pharmaceutical companies and other stakeholders.

Applicants

Country

Gevers, Tom  (Principal applicant)

Dept. Internal medicine, Gastroenterology, Maastricht UMC

The Netherlands

Sebode, Marcial

Dept. Medicine; University Medical Centre Hamburg-Eppendorf

Germany

Janik, Maciej

Liver and Internal Medicine Unit, Medical University of Warsaw

Poland

Willemse, José

Dutch Liver Patients Association

The Netherlands

Drenth, Joost P.H.

Dept. Gastroenterology and Hepatology, Radboudumc, Nijmegen

The Netherlands

Milkiewicz, Piotr

Liver and Internal Medicine Unit, Medical University of Warsaw

Poland

Lohse, Ansgar

Dept. Medicine; University Medical Centre Hamburg-Eppendorf

Germany

Snijders, Romeé

Dept. Gastroenterology and Hepatology, Radboudumc, Nijmegen

The Netherlands

Abstract

Autoimmune hepatitis (AIH) is a lifelong liver disease characterized by inflammation resulting in substantial complaints or even death with many unanswered clinical and research questions. The AIH research workshop is initiated to resolve these issues and will focus on three important unresolved aspects of AIH:

  1. Pathogenesis and immunoregulation (Getting the diagnosis),
  2. Novel immunotherapeutic approaches (Getting the best treatment) and
  3. Quality of life.

Next to future orientated presentations held by experienced researchers from throughout Europe, parallel workshops will be organized to tackle topics based on clinical unmet needs and patients will speak about their patient journey, unmet needs and quality of life. We plan to have patients from Western and Eastern European countries. This workshop will be a collaboration between the ERN RARE-LIVER and the International AIH Group (IAIHG). We will invite physicians (adult and pediatrician), basic/clinical researchers, pathologists, immunologists, patient and representatives. This face-to-face workshop will be organized 3rd and 4th of June 2022 in Maastricht, the Netherlands. This workshop will bring together all expertise and patients journeys from Western and Eastern Europa to identify the most important gaps, make the best use from all disciplines and create a coordinated structure to bring AIH care to a higher level. In addition, it will lay the groundwork for new high level research networks that will aim for additional applications within the three aforementioned topics.

Applicants

Country

De Bruyne, Ruth (Principal applicant)

Dept. Paediatric Gastroenterology and Hepatology, Ghent University Hospital

Belgium

Vanden Wyngaert, Karsten

Paediatric Dept., Ghent University Hospital

Belgium

Thomsen, Ena Lindhart

Dept Paediatrics and Adolescent Medicine, Copenhagen University Hospital

Denmark

Samyn, Marianne

Dept. Paediatric Liver, GI and Nutrition Centre, King’s college hospital NHS Foundation Trust, London

United Kingdom

Kelly, Deirdre

Liver Unit, Birmingham Women’s & Children’s Hospital

United Kingdom

Day, Jemma

Institute of liver studies, King’s College Hospital, London

United Kingdom

Marino, Zoe

Liver unit; Hospital Clinic Barcelona

Spain

Willemse, José

Dutch Liver Patients Association

The Netherlands

Van Staa, AnneLoes

Research Centre Healthcare Innovation, Rotterdam University of Applied Sciences

The Netherlands

Abstract

Transition is defined as the gradual and planned shift from paediatric to adult care. The transition of patients with rare liver disease is often suboptimal, resulting in poor health outcome and a considerable loss-to-follow-up. To our knowledge, transitional care in rare liver disease is poorly understood and investigated compared to chronic kidney disease, organ transplantation or cystic fibrosis. Based on a survey circulated to stakeholders in Europe, we identified gaps and barriers on the implementation of transitional care in patients with rare liver disease. We apply for this funding to organize a workshop, that will result in a plan of action to improve age-appropriate and transitional care in patients with rare liver disease. All following stakeholders will be actively engaged in the organisation and participation: (i) paediatric and adult physicians, (ii) transition specialists (nurses, coordinators, researchers), (iii) patients, parents and PAO’s, and (iv) psychologists. The stakeholders will participate into a constructive brainstorm addressing the psycho-social and organisational barriers, and definition of best outcome parameters. The brainstorm-sessions will be concluded with a step-by-step process to deliver a plan of action that is applicable throughout Europe. Other deliverables are: (i) the development of self-management support tools and improvement of patient participation, (ii) a consensus on best outcome parameters, (iii) a definition of the needs for further educational programs, and (iv) a framework for a cross-ERN event on transition.

 

Applicants

Country

Bezzina, Connie (Principal applicant)

Dept. Experimental Cardiology, Amsterdam UMC

The Netherlands

Walsh, Roddy

Dept. Experimental Cardiology, Amsterdam UMC

The Netherlands

Jurcut, Ruxandra

Dept. Cardiology, Emergency Institute For Cardiovascular Diseases “PROF.DR.C.C.Iliescu”, Bucharest

Romania

Crotti, Lia

Dept. Cardiology, IRCCS Istituto Auxologico Italiano and University Milano Bicocca

Italy

Hasdemir, Can

Dept. Cardiology, Ege University School of Medicine, Izmir

Turkey

Behr, Elijah

Cardiology Section, St George’s, University of London

United Kingdom

Barc, Julien

l’institut du thorax, Inserm UMR 1087/CNRS UMR

6291, Nantes

France

Biller, Ruth

ARVC-Selbsthilfe e.V.

Germany

Kääb, Stefan

Dept. Medicine 1, University Hospital Ludwig Maximilians University, Munich

Germany

Van Tintelen, Peter

Dept. Genetics, University Medical Center Utrecht

The Netherlands

Abstract

Inherited arrhythmia syndromes are a group of rare genetic diseases that lead to sudden cardiac death in young people. By identifying the genetic variants that underlie these conditions, we can identify those individuals at risk of developing potentially fatal arrhythmias, for example family members (siblings, children etc.) of patients already diagnosed with arrhythmia syndromes. At-risk individuals can then avail of clinical monitoring (e.g. ECG tests) and potentially early prophylactic treatment if deemed to be at high risk.

While much progress has been made in the last 20-30 years to identify the genetic factors that cause these conditions, it is now recognised that a more complex range of genetic factors often underlies the risk of developing these conditions and the potentially fatal cardiac events. By improving our understanding of these factors, we will be able to more accurately predict the risk in patients, their family members and eventually the population at large. This will enable more accurate diagnosis and more focused clinical interventions, with the aim to reduce the incidence of sudden cardiac death from these conditions.

Because these are relatively rare diseases, collaboration across different research centres, hospitals and countries is essential in order to design research studies at the scale necessary to make new genetic discoveries. This networking event will build upon existing collaborations and foster new partnerships between many of the leading researchers and research centres in this field.

 

Applicants

Country

Villasante,  Aranzazu (Principal applicant)

Institute for Bioengineering of Catalonia (IBEC), Barcelona

Spain

Westermann, Frank

Dept. Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg

Germany

Mora, Jaume

Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Deu. Barcelona

Spain

Gallo, Juan

Dept. Health, International Iberian Nanotechnology Laboratory, INL, Braga

Portugal

Veselska, Renata

Dept Experimental Biology, Masaryk University, Brno

Czech Republic

Bedoya Reina, Oscar

Dept. Microbiology, Tumor and Cell, Karolinska Institute, Solna

Sweden

Piskareva, Olga

Dept. Anatomy and Regenerative Medicine, RCSI University of Health and Medical Sciences, Dublin

Ireland

Molí, Joaquín

Association of Families and Friends of Children with Neuroblastoma (NEN)

Spain

Abstract

Neuroblastoma (NB) is a rare cancer and the most common extracranial solid tumor of childhood diagnosed in the first year of life. For high-risk patients, long-term survival is barely 50% despite surgery and chemotherapy. Importantly, more than 40% of children suffer drug resistance and tumor relapse during or after treatment. Thus, researchers and clinicians continue searching for innovative therapies for patients with NB despite the progress made.

This networking event brings together experts from different fields but with the same objective- to join forces to fight NB and accelerate new treatments discovery. To this end, the main aim of the networking event is to share knowledge on NB between physicians, researchers, and members of patient advocacy organizations, and build up a research consortium to actively participate in the Europe’s Beating Cancer Plan.

The symposium will be held at the Sant Joan de Deu Hospital in the greater Barcelona area (Spain); it will be carried out in four sessions to discuss new advancements in NB characterization and modeling, cutting-edge technologies, and current strategies for NB therapy. In addition, the network event will serve to bring knowledge for all participants, build up new research networks, and disseminate the event conclusions to the general public, thanks to the support of the Association of Families and Friends of Children with Neuroblastoma (NEN). Finally, the symposium encourages the participation of Early Career Researchers and enables involvement in the network of usually underrepresented countries in Europe.

Applicants

Country

Smeets, Bert (Principal applicant)

Dept. Toxicogenomics, Maastricht University.  

The Netherlands

Verbrugge, Bram

LAMA2-Europe (representing PAOs “Voor Sara”(NL), “Impulsa” (E) and LAMA2FR (F))

The Netherlands

Rüegg, Markus A.

Biozentrum, University of Basel

Switzerland

Durbeej, Madeleine

Dept. Experimental Medical Science, Lund University

Sweden

Stępniewski, Jacek

Faculty of Biochemistry, Biophysics and Biotechnology; Dept Medical Biotechnology, Jagiellonian University, Krakow

Poland

Topaglu, Haluk

Dept. Pediatrics, Yeditepe University, Istanbul

Turkey

Sarkozy, Anna

Dubowitz Neuromuscular Centre, Great Ormond Street Hospital, London

United Kingdom

Allamand, Valérie

Research Center in Myology, Sorbonne Universite-Inserm UMRS974, Paris

France

Abstract

Laminin-a2 Muscular Dystrophy (LAMA2-MD), the congenital form known as Merosin-Deficient Congenital Dystrophy Type 1A (MDC1A), is a neuromuscular dystrophy that affects 1-4 in every 100,000 individuals. The disorder, for which no cure is available, causes muscle weakness and wasting, together with joint contractures and nervous system involvement. A variety of pathogenic variants in the LAMA2 gene leads to either a complete or partial deficiency of laminin-a2, with, respective, severe and mild clinical manifestation. LAMA2-MD is ultra-rare, diagnosis is difficult and clinical expression is heterogeneous, requiring international collaboration.

The organizing consortium of the networking event consists of the main clinical and research groups and patient organizations in the EU, but key participants will be invited from all over the world. The outcomes will be disseminated to all European and affiliated countries.

The first day of the 3-day event will focus on patient registries and ongoing natural history studies to align them and define biomarkers and guidelines which can be used in patient-care. The second day, in which the patient is central, will focus on defining diagnostic criteria and guidelines for alleviating symptoms and maintaining quality of life. These will be distributed among patients, patient organizations and clinicians throughout Europe. On the third day therapy development for LAMA2-MD will be central by making an inventory of available patient samples for research, sharing confidential research progress and establishing a LAMA2-MD therapy task-force.

Applicants

Country

Van Ravenswaaij-Arts, Conny (Principal applicant)

Dept. Genetics, University Medical Centre Groningen

The Netherlands

Schön, Michael

Dept Anatomy, Ulm University

Germany

Hadzsiev, Kinga

Dept. Medical Genetics, University of Pécs

Hungary

Matulevičienė, Aušra

Medical Genetics Center, Vilnius University Hospital Santaros Klinikos

Lithuania

Haeger, Irina

Phelan-McDermid-Gesellschaft e.v.

Germany

Vyshka, Klea

Dept Clinical Genetics, Robert Debré University Hospital, Paris

France

Abstract

In 2020 a European consortium on Phelan-McDermid syndrome (PMS) started to write a best practice clinical guideline supported by the European Reference Network on neurodevelopmental disorders ERN-ITHACA. The consortium consists of over 70 members, representing 15 European countries and including 11 patient representatives. The group had their first online meeting in October 2020 and currently the guideline is nearing its completion. While working on the guideline, knowledge gaps were identified as well as the need for a European database enabling the collection of more data on the natural history of PMS, especially on the often observed mental health problems. The consortium now feels the need to meet face-to-face in order to discuss the guideline recommendations and to strengthen the collaboration in order to tackle the knowledge gaps that we identified, as well as to discuss how best to proceed with the database. Most importantly, we are looking forward to discussions with our patient representatives who are invited to present their views early in the meeting programme.

The meeting will be hosted in June 2022, by the centre of expertise for PMS of the UMC Groningen, Netherlands, and the outcomes of the meeting will be:

  • a strong collaboration between different European research groups and centres of expertise for Phelan-McDermid syndrome
  • insight in the needs of the patient representatives and strengthen their participation in research
  • a priority list of knowledge gaps that need to be studied
  • consensus on the variables to be collected in the European PMS database.

 

Applicants

Country

Bertoletti, Monica (Principal applicant)

AIBWS Italia

Italy

Dan, Dorica

Romanian National Alliance for Rare Diseases

Romania

Pogany, Gabor

Hungarian Federation of people with rare and congenital diseases (HUFERDIS)

Hungary

Mussa, Alessandro

Dept. Public Health and Pediatrics, University of Torino

Italy

Martin, Pablo

Asociación Española del Síndrome de Beckwith-Wiedemann (ASEBEWI)

Spain

Tannorella, Pierpaola

Cytogenetics and Molecular Genetics laboratory, Istituto Auxologico Italiano IRCCS, MIlan

Italy

Jacobsson, Linda

BWS Swerige

Sweden

Skorga, Agata

Dept. Medical Genetics, The Childrens Memorial Health Institute, Warsaw

Poland

Lapunzina, Pablo

Dept. Genetics, INGEMM, Hospital la Paz, Madrid

Spain

Abstract

Beckwith-Wiedemann Syndrome (BWS) is a congenital syndrome of cellular overgrowth, causing about thirty different symptoms including a greater predisposition to the development of embryonic tumors affecting internal organs, hypertrophy, and macroglossia. There are no pharmacological therapies to cure it.

The 1st International Congress on BWS will be held from 2 to 5 June 2022 and will be available in hybrid mode, live in Cervia (Italy), and in online streaming.

The event is organized by several PAO in collaboration with doctors and researchers; the goal is to spread new knowledge on some specific aspects and implement the international network of families, caregivers, doctors, and researchers.

There will be two focuses: from the research point of view, five topics will be treated by sharing the preliminary and definitive results of various studies and data collections; from the point of view of dissemination, the specialists will train families starting from the basic notions up to the future perspectives. In the working sessions, dedicated exclusively to experts, the following topics will be covered: heterometry of the lower limbs, treatments in macroglossia, screening strategies for hepatoblastoma, reflections on the psychological dimension of living with BWS, limits of prenatal diagnosis, data collection for adults with BWS.

 

Applicants

Country

Callewaert, Bert (Principal applicant)

Dept. Biomolecular Medicine and Centre for Medical Genetics, Ghent University

Belgium

Boiteux, Marie-Claude

Cutis Laxa Internationale

France

Gardeitchik, Thatjana

Dept. Human Genetics, Radboud University Medical Center, Nijmegen

The Netherlands

Aelbrecht, Karolien

Dept. Biomolecular Medicine and Centre for Medical Genetics, Ghent University

Belgium

Kornak, Uwe

Institut für humangenetik, Universitätsmedizin Göttingen

Germany

Bodemer, Christine

Service de dermatologie et vénéréologie, Hôpital Necker-Enfants maladies Hospital, Université de Paris

France

Abstract

Cutis laxa (CL) syndromes combine a large group of heritable disorders characterized by a loose, redundant skin. The many entities differ in systemic manifestations affecting the lung, heart and blood vessels, urinary tract, bowel, eye, skeleton, and neurological systems. Due to the extreme rarity, clinical knowledge on CL is limited and scattered in case reports and patients often lack correct information and disease management. Exchange of knowledge is of utmost importance for clinical care and for identifying unrecognized manifestations, including psychological and musculoskeletal burdens. Hence, a coordinated clinical research approach, instead of separate research endeavours by different research groups is required.

We will organize a hybrid international networking event at Ghent University, Belgium, in September 2022. We will bring together affected individuals and their care givers, physicians, paramedics and researchers. A clinic day (Sept 14, 2022) will allow patient participation in research. Focus groups will identify major disease burdens, patient needs and expectations, will allow for exchange of experiences and coping strategies, and establish a basis for patient centred research approaches. A conference day (Sept 15, 2022) will provide a state-of-the-art on CL and create interaction between stakeholders. A research day (Sept 16, 2022) will gather all stakeholders to coordinate and plan international research endeavours. We expect this conference to provide a global patient centred approach to advance awareness, care and research in CL.

 

Applicants

Country

Behl, Katherine (Principal applicant)

Alternating Hemiplegia of Childhood UK Charity

United Kingdom

Vranckx, Bridget

AESHA, Spanish Association of Alternating Hemiplegia of Childhood

Spain

Lentze-Tuijn, Nienke

AHC Association, The Netherlands

The Netherlands

Skibińska-Mamzer, Ilona

Polish Association ahc-pl

Poland

Parowicz, Marek

Alternating Hemiplegia of Childhood 18+

Germany

Van den Maagdenberg, Arn

Dept. Human Genetics, Leiden University Medical Center

The Netherlands

Vezyroglou, Aikaterini

Dept. Developmental Neurosciences, University College London, Great Ormond Street Institute of Child Health

United Kingdom

Sisodiya, Sanjay

Dept. Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London

United Kingdom

Balestrini, Simona

Dept. Clinical and Experimental Epilepsy, University College of London

United Kingdom

Abstract

The Story of AHC: the past, the present and the future: Celebrating 10 years since the discovery of the ATP1A3 disease and developing goals for the next ten years for AHC and ATP1A3 research.

In 2022 it is 10 years since the discovery of the ATP1A3 gene. This was a scientific breakthrough in understanding the underlying cause of Alternating Hemiplegia of Childhood. This discovery involved an international collaboration between researchers, clinicians and families living with the condition. Since the discovery, more conditions within the spectrum of ATP1A3 gene diseases have been discovered.

AHC and ATP1A3 diseases are ultra-rare neuro-developmental lifelong conditions. They present with many neurological symptoms and can affect other parts of the body too. All code for a faulty cell membrane pump affecting the movement of sodium and potassium. Understanding all the ATP1A3 diseases can help progress research and improve the lives of those living with these painful and debilitating conditions.

The knowledge of AHC and ATP1A3 diseases have grown substantially over the last ten years, however, there sadly remains no effective treatment for this condition. This conference aims to bring together researchers, clinicians, and families to discuss current research and drive forward goals in research for the next ten years.

 

Round 8 (Collection date March 2022)

Read more about the event

Applicants

Country

Leonardi, Nora (Principal applicant)

AGO2 Association

Switzerland

Lessel, Davor

Dept. Human Genetics, University Medical Center Hamburg-Eppendorf

Germany

Piton, Amélie

Laboratoire de diagnostic génétique / Institut de Génétique Biologie, Moléculaire et Cellulaire (IGBMC), Strasbourg University Hospital

France

Kreienkamp, Hans-Jürgen

Dept. Human Genetics, University Medical Center Hamburg-Eppendorf

Germany

Meister, Gunter

Dept. Biochemistry, University of Regensburg

Germany

Abstract

AGO1 and Lessel-Kreienkamp syndromes are ultra-rare genetic conditions caused by mutations in the AGO1/AGO2 genes. They can be apparent from infancy and, while outcomes vary, are characterized by significant global developmental delay with intellectual disability, language problems and delayed motor development. Notably, the link between where a mutation lies on the gene and the patient’s symptoms, also known as genotype-phenotype, is extremely similar across the two conditions. Because these conditions have only just been discovered, they are not yet well understood and are likely under diagnosed.

AGO1 and AGO2 belong to the Argonaute protein family, and are critical for the regulation of gene expression via RNA interference. This regulation may be faulty in children with mutations in AGO1 or AGO2.

The first Argonaute Syndrome Science & Family conference will be held in Regensburg on August 27-28, 2022 in a hybrid format, and bring together patient families, researchers and clinicians of the AGO1 and AGO2 communities to facilitate the sharing of knowledge. The goals are to enhance understanding of the underlying clinical, molecular and biological characteristics of each syndrome and of genotype-phenotype relationships, to foster ideas and collaborations for next steps in research that may eventually lead to novel disease-modifying therapies, and to unite patient families.

The meeting will be preceded by an international conference on Argonaute proteins and participants of either are invited to attend the other conference.

Applicants

Country

Capone, Donatella (Principal applicant)

Nana Onlus

Italy

Voso, Maria Teresa

Dept. Biomedicine and Prevention, University of Rome Tor Vergata

Italy

Döhner, Konstanze

Dept Internal Medicine III, University Hospital of Ulm

Germany

Dillon, Richard

Dept. Medical and Molecular Genetics, King’s College, London

United Kingdom

Yuksel, Meltem Kurt

Dept. Hematology and Stem Cell Transplantation, Ankara University School of Medicine

Turkey

Ghahramanyan, Nerses

Dept. Inpatient Onco-Hematology and Chemotherapy, Hematology Center after Yeolyan, Yerevan

Armenia

Abstract

Cancer is a malignant disease in which some of the body’s cells grow uncontrollably. A malignant disease may unexpectedly recur as some forms of blood cancer collectively called therapy-related myeloid neoplasms (t-MN). These rare cancers occur secondarily to chemo/radiotherapy used in the case of a primary cancer, autoimmune disease or solid organ transplant. Unfortunately, once manifested, the life expectancy of t-MN patients is a few months.

The rarity of t-MN justify the relatively little attention to this disease in the last 15 years, although with significant knowledge improvements over the last 5 years.

Among cancer survivors, t-MN incidence definitely calls for urgent action: one of 200 breast cancer patients, one of 10 patients treated for non-Hodgkin lymphoma and up to 1.0% of children treated for hematological, solid and central nervous system cancers develop t-MN.

Prompted by a story of positive interaction between an energetic small PAO and the European research group led by the first co-applicant, the proposed workshop will take stock of t-MN scientific knowledge, offering important tools in the recognition and clinical management of t-MN, creating a constructive debate for innovative point-of-view and essential advancements in the field.

A network of skilled European researchers will generate the basis for prevention and cure t-MN development, investigating the type and dosage of cancer therapy, aging process, inherited and environmental risk factors and genetic abnormalities in hematopoietic stem cells.

Applicants

Country

Gonçalves Costa, Isabel  (Principal applicant)

Dept. Pediatric / UHTHP (Liver Unit), CHUC (Centro Hospitalar e Universitário de Coimbra)

Portugal

Diogo Matos, Luísa

Dept. Child Development Centre- Hospital Pediátrico, CHUC (Centro Hospitalar e Universitário de Coimbra) 

Portugal

Ferreira, Sandra

Dept Pediatric / Pediatric Hepatology and Liver Transplantation Unit (UHTHP), CHUC (Centro Hospitalar e Universitário de Coimbra)

Portugal

Dionisi-Vici, Carlo

Dept. Pediatric Subspecialities, Ospedale Pediatrico Bambino Gesù IRCCS, Rome

Italy

Herden, Uta

Dept. Visceral Transplantation, University Medical Center Hamburg-

Eppendorf

Germany

Willemse, José

Dutch Liver Patients Association

The Netherlands

Abstract

Inborn errors of metabolism (IEM) are a heterogenous group of diseases that can result in significant morbidity. Management can be challenging and arduous for families. It can include dietary restrictions, therapies to remove toxic metabolites, and diverse critical supplements, among others. Despite optimal management, life-threatening decompensation may occur leading to significant health and neurodevelopmental risks.

Liver transplantation (LT) is increasingly considered an effective treatment option for various IEM. We apply for this funding to organize a workshop on Liver Transplantation for IEM, joining paediatric, adult physicians, Patient Associations and PAO’s from three European Reference Networks (ERNs): RARE-LIVER, MetabERN, and TransplantChild. By working together it will not only become possible to share different types of knowledge and expertise but also expand the range of perspectives upon this theme. We aim to address issues around this topic. Highlights of the discussion will be: optimal timing for LT, challenging indications, maximizing organ donation for IEM, indications for combined liver-kidney transplant, risk-benefit decisions.

As a result of this meeting, we expect to provide practical updates and a consensus on liver transplantation for IEM. Other goals are: (i) to update leaflets or other educational tools for patients and families; (ii) to become aware of patients/families’ unmet needs and develop strategies to address them; (iii) to promote parallel sessions with Patient Advocacy Organisations. The meeting will be held in Portugal in April 2023.

Applicants

Country

Jenner, Rebecca (Principal applicant)

Rett Syndrome Europe

Luxembourg

Adamek, Robert

RETT UK

United Kingdom

Szili, Danijela

Hungarian Rett Syndrome Association

Hungary

van den Berg, Mariëlle

Dutch Rett Syndrome Association

The Netherlands

Townend, Gillian

Faculty of Health, Medicine & Life Sciences, Maastricht University

The Netherlands

Guil, Sònia

Regulatory RNA and chromatin group, Josep Carreras Leukaemia Research Institute, Barcelona

Spain

Abstract

Imagine being told the toddler you thought was healthy, but perhaps slow to progress, had a rare devastating disability that would leave them needing lifelong 24/7 care. That is the reality for parents receiving a diagnosis of Rett syndrome (RTT) for their child. Although present at birth, RTT is not usually undetected until a major regression occurs at around two years of age. Children lose acquired skills and the complexity of the disability is revealed. RTT is a severe, life long, life limiting genetic neurological disorder, affecting 1 in 10,000, mainly females. There is no treatment but recent advances in gene therapy could provide something transformative or even a cure.

With the main meeting in Hungary (Feb 2023), members of Rett Syndrome Europe (RSE) Scientific Advisory Board (SAB) and others would present to parent carers, clinicians, therapists and researchers, with opportunities for discussion and Q&As. This will be live streamed to other countries where small groups of key stakeholders will meet allowing for discussion. Day 1 will focus on basic/translational talks and Day 2 on family orientated/therapy talks.

The event will improve quality of life for people with RTT (PwRs) and their families in countries where support, information and advice is lacking. It will encourage new research collaborations, particularly in areas where there are gaps in knowledge. With the prospect of a transformative treatment within reach, the development of patient organisations to facilitate clinical trial recruitment and engagement with EMA and regulatory bodies is crucial.

Applicants

Country

Cagalinec, Michal (Principal applicant)

Dept. Cellular Cardiology, Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava

Slovakia

Delprat, Benjamin

Mécanismes moléculaires dans les démences neurodégénératives (MMDN), INSERM, Montpellier

France

Bultynck, Geert

Cellular and Molecular Medicine, Laboratory of Molecular & Cellular Signaling, KU Leuven

Belgium

Verfaillie, Catherine

Lab. Molecular & Cellular Signaling, Development and regeneration, Stem Cell Institute, KU Leuven

Belgium

Kaasik, Allen

Dept. Pharmacology, University of Tartu

Estonia

Lievens, Jean-Charles

MMDN U1198 INSERM, Montpellier

France

Schmitt, Martine

Faculté de Pharmacie, Laboratoire d’Innovation Thérapeutique, University of Strasbourg, Illkirch

France

Abstract

Cells execute their specialized functions through specific compartments, so-called organelles. These organelles do not function independently of each other, but are actually closely connected through membrane contact sites. The contact sites between two of the organelles, endoplasmic reticulum and mitochondria, named MAMs serve as hubs for signalling. It has become increasingly clear that such contact sites play a key role in cellular health and cell function. Therefore, the time is ready to translate these findings and understand how MAMs are dysregulated in rare diseases, how MAM dysregulation contributes to disease progression and whether restoring MAMs integrity and functionality can improve disease outcomes. At the event, we will discuss the latest advances in understanding the function of MAMs in cells and how they are vital in human health and disease with particular focus on the medical domain of rare diseases that are associated with neurodegeneration. The event will bring together basic, pre-clinical and clinical expert teams that work on MAMs, signalling and/or rare diseases, including the team leaders as well as early carrier scientists and PhD students who will present their latest and unpublished findings in seminar talks and poster presentations. The event will take place in Bratislava, Slovakia, the home city of one of the consortium members, on October 6-7th, 2022. The aim is to organize an in-person meeting with a hybrid component to lower the barrier for attendance by any interested researcher who might face challenges to travel in-person.

Round 9 (Collection date September 2022)

Applicants

Country

Pérez de Castro, Ignacio (Principal applicant)

Instituto de Salud Carlos III, Instituto de Investigación de Enfermedades Raras, Madrid

Spain

Schirmer, Eric

Dept. Institute of Cell Biology, University of Edinburgh

United Kingdom

Bonne, Gisèle

Center of Research in Myology, Sorbonne University, Paris

France

Andrés, Vicente

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid

Spain

Lattanzi, Giovanna

CNR Institute of Molecular Genetics Unit of Bologna

Italy

Hamczyk, Magda

Dept. Biochemistry and Molecular Biology, University of Oviedo

Spain

Madej-Pilarczyk, Agnieszka

Dept. Medical Genetics, The Children’s Memorial Health Institute (CMHI), Warsaw

Poland

Araújo-Vilar, David

Dept. Psychiatry, Radiology, Public Health, Nursing and Medicine, University of Santiago de Compostela

Spain

Wahbi, Karim

Dept. Cardiology, Paris Cité University, Cochin hospital

France

Veltrop, Rogier

LMNA cardiac / LMNA related cardiac diseases network (LMNAcadiac.org)

The Netherlands

Abstract
The 4th International Meeting on Laminopathies will bring together a wide range of experts in the field of these rare diseases caused by mutations in genes encoding proteins of the nuclear envelope. Laminopathies can affect single tissues (mainly striated muscle, adipose tissue and peripheral nerve) or multiple organs. Hence, most laminopathies can be classified in 4 different disease groups: muscular dystrophies, lipodystrophies, peripheral neuropathies and progeroid disorders. Numerous mutations have been associated with laminopathies, but the mechanisms underlying disease initiation and progression remain poorly characterized. Accordingly, there is a lack of specific and effective treatments for laminopathies. The meeting, to be celebrated in Madrid on May 9-12, 2023 on a face-to-face format, will be open to researchers, physicians and patients from around the world with the main goal of synergistically exchange knowledge and ideas to better understand laminopathies and help develop new therapies. The meeting will include basic-molecular, disease-modeling, as well as therapeutic and clinical sessions. Patients will be part of the meeting in a specific session co-organized with scientists. The number of participants (~200) and format of the event will promote the dialogue between all the main stakeholders involved in the study of laminopathies. In summary, the 4th International Meeting on Laminopathies will be a multidisciplinary scientific meeting focused on helping researchers and clinicians to find effective therapies and eventually the cure for laminopathies.

Applicants

Country

Dantone, Stefania (Principal applicant)

SCN2A ITALIA Famiglie in Rete APS, Padua

Italy

Fazeli, Walid

Dept. Neurology, University Hospital Bonn

Germany

Gardella, Elena

Dept. Clinical genetics and clinical neurophysiology, Danish Epilepsy Centre, Dianalund

Denmark

Scarcelli, Vincenza

SCN8A ITALIA ODV, Milan

Italy

Kaden, Svenja

SCN2A Germany e.V., Walldorf

Germany

Johannesen, Katrine

Dept. Clinical genetics and precision medicine, Danish Epilepsy Centre, Dianalund

Denmark

Chokheli, Zhana

SCN2A Georgian Association, Tbilisi

Georgia

Cabanach, Gregori

SCN8A France, Pierrevert

France

Clay, Joy

SCN8A UK and Ireland, Liverpool

United Kingdom

Aledo- Serrano, Angel

Dept. Neurology – Epilepsy Program, Hospital Ruber Internacional, INCE Foundation, Madrid

Spain

Abstract
The two genes SCN2A and SCN8A both encode for distinct neuronal sodium channels. Mutations of the genes SCN2A or SCN8A are associated with epilepsy, autism spectrum disorder, intellectual disability, movement disorders and sudden unexpected death in epilepsy patients (SUDEP). As rare sodium-channel disorders, they share commonality of research but they require distinct treatment and expertise, e.g. due to their divergent roles during brain development. Improved awareness and early diagnosis are crucial for the patients.

The first European SCN2A/SCN8A Conference (Germany, 2021) put the seed for the birth of several SCN2A & SCN8A patient advocacy organisations forming active networks and beginning to share knowledge and educational events. The future Conference will take place in Denmark (May 26-27, 2023) focusing on common aspects of SCN2A/SCN8A transnational research: clinicians, researchers and patient advocates will have the possibility to enhance the intersection of data and expertise, enriching knowledge of optimum therapies and stimulating ideas for new research streams. The event (virtual alternative provided) will pay particular attention to patient registries and Natural History Studies, but also to new areas of research such as how to translate results of preclinical studies into clinics and to address the best precision medicine possible. Updates on socio-economic impact of both diseases will be presented as real-world study.

Also, members from underrepresented countries will share their unmet needs and discuss how the scientific community can address them.

Applicants

Country

Zdolšek Draksler, Tanja (Principal applicant)

Center for knowledge transfer in IT, Jozef Stefan Institute, Ljubljana

Slovenia

Kleefstra, Tjitske

Dept. Human Genetics, RadboudUMC, Nijmegen/Dept. Clinical Genetics, ErasmusMC, Rotterdam

The Netherlands

Lovrečić, Luca

Clinical Institute for Genomic Medicine, University medical centre Ljubljana

Slovenia

Mandel, Jean-Louis

Dept. Neurogenetics and Translational Medicine, Institut de Génétique et de Biologie Moléculaire et Cellulaire, University of Strasbourg

France

Hocking, Wendy

Kleefstra syndrome UK, Skelton, Cleveland

United Kingdom

Tzimourta, Katerina

Dept. Electrical and Computer Engineering, University of Western Macedonia, Kozani

Greece

Fekonja, Špela

IDefine Europe, Foundation for the Advanced Treatment of Rare Genetic Diseases, Slovenske Konjice

Slovenia

 

Abstract
The networking event will be held in June 2023) in Ljubljana, Slovenia. The event will focus on Kleefstra syndrome, a rare genetic disorder with app. 1000 diagnosed patients worldwide. Due to the rarity of the disease, a global perspective is needed to foster new research insights. The event will bring together Kleefstra syndrome PAOs, researchers & clinicians from different domains having a common interest: share new research findings related to Kleefstra syndrome that will lead the Kleefstra community to optimise current care and to reach their final goal, the discovering of a life-changing treatment and cure for Kleefstra syndrome. A special focus will be given to artificial intelligence (AI), which is generally still something new for the rare disease communities, but it can play a crucial role, especially in shortening the time needed for new research insights.

Applicants

Country

Balagura, Ganna (Principal applicant)

Pediatric Neurology Unit, IRCCS G. Gaslini Institute, DINOGMI, University of Genova

Italy

Verhage, Matthijs

Dept. Functional Genomics, Center for Neurogenomics and Cognitive Research, VU University Amsterdam

The Netherlands

Furia, Francesca

Dept. Clinical Genetics, Danish Epilepsy Centre / University of Southern Denmark

Denmark

Stamberger, Hannah

Applied and translational Neurogenetics group and Dept Neurology, Center of Molecular Neurology, VIB, University of Antwerp and University Hospital Antwerp

Belgium

Syrbe, Steffen

Div. Pediatric Epileptology, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg

Germany

Milh, Mathieu

Pediatric neurology Unit, Aix-Marseille Univ and Assistance Publique Hopitaux de Marseille

France

Garcia Cazorla, Angeles

Dept. Neurology, Hospital Sant Joan de Déu, Barcelona

Spain

Serdaroglu, Esra

Dept. Child Neurology, Gazi University, Ankara

Türkiye

Striano, Pasquale

Pediatric Neurology Unit, IRCCS G. Gaslini Institute, DINOGMI, University of Genova

Italy

Frassine, Lorenzo

STXBP1 ITALIA APS, San Lazzaro di Savena

Italy

 

Abstract
STXBP1-encephalopathy (STXBP1-E) is a rare genetic neurodevelopmental disorder, caused by pathogenic variants in the STXBP1 gene, with an estimated incidence of 1 in 30.000. STXBP1-E is characterised by developmental delay often leading to (severe) intellectual disability, and seizures in most patients. Behavioural problems and movement disorders such as tremor and ataxia are frequent comorbidities. At the moment there is no cure and treatment is limited to symptom control. With this first European STXBP1 summit we want to connect healthcare professionals and fundamental researchers working on STXBP1 with patients and their caregivers. The aim of this event is to promote collaborative networks, share knowledge and create awareness on STXBP1-E. We strongly believe that we can only advance our understanding of this rare disorder and advance the search for a cure by extensive collaboration with both the international research community and the STXBP1 families who have their own personal expertise with the disease. To this aim, we invite professionals and patient advocates from all over Europe, also specifically addressing underrepresented countries, to join the 1st European STXBP1 Summit

 

Applicants

Country

Miroševič, Špela (Principal applicant)

CTNNB1 Foundation, Foundation for Research in the Field of Gene Therapy, Ljubljana

Slovenia

Martin Medina, Estibaliz

Asociación CTNNB1, Basauri, Vizcaya

Spain

Osredkar, Damjan

Dept. Pediatric Neurology, University Children’s Hospital Ljubljana

Slovenia

Forstnerič, Vida

Dept. Synthetic Biology and Immunology, National Institute of Chemistry, Ljubljana

Slovenia

Ferraro, Mirela

CTNNB1 Italia, Acri (CS)

Italy

 

Abstract
CTNNB1 Syndrome is a rare and severe neurodevelopmental associated with general developmental delay, intellectual disability, visual defects, autistic behaviours and speech delay. Reports show that many CTNNB1 patients are commonly misdiagnosed with cerebral palsy, suggesting that the actual number of affected persons is greatly underestimated. In addition, to date there is no cure for CTNNB1 syndrome. Nevertheless, the effort of patient advocacy organisations (PAOs) has been crucial to build a community where patients and their families share experiences on current management techniques such as physical therapy and pharmacological treatments that help manage certain symptoms. In addition, the joint effort of PAOs has accelerated the development of advanced therapies, as demonstrated in the progress made in the past year: building a global network of researchers and supporting scientific projects.

To bring the CTNNB1 community closer together, the CTNNB1 Foundation and Asociación CTNNB1 organize the 1st International CTNNB1 Syndrome Conference on 23 -24th March 2023 in Madrid, Spain. The event will bring together professionals and patients committed to raise awareness, share knowledge,

and improve the lives of CTNNB1 patients. The event has three key objectives:

  • bring together patients and promote sharing of experiences,
  • (ii) centralize knowledge and practices on current management techniques and perspectives,
  • (iii) connect researchers working on CTNNB1 syndrome and present research updates on treatment solutions.

 

Applicants

Country

Ünsal, Evrim (Principal applicant)

Dept. Medical Genetics, Yüksek İhtisas University Faculty of Medicine, Ankara

Türkiye

Alcaraz Mas, Luis Antonio

Dept. Agrochemistry and Biochemistry, University of Alicante

Spain

Balogh, I

Dept. Clinical Genetics, University of Debrecen

Hungary

Baltacı, Volkan

Dept. Medical Genetics, Yüksek İhtisas University, Ankara

Türkiye

Özer, Leyla

Dept. Medical Genetics, Yüksek İhtisas University, Ankara

Türkiye

Ata, Barış

Dept. Obstetrics and Gynecology, Koç University School of Medicine, İstanbul

Türkiye

Balaban, Başak

In-vitro Fertilization Laboratory, American Hospital, İstanbul

Türkiye

Aktuna, Süleyman

Dept. Medical Genetics, Yüksek İhtisas University, Ankara

Türkiye

Abstract
Reproductive years are both special and challenging in various aspects for all women. However for women with rare disease problem this period comes with its more complicated conditions to tackle. From making the decision of building up a family to giving birth to a baby, this highly personal and sensitive season requires step-by-step intervention of various stakeholders such as family members, medical professionals, government agencies, policy makers etc. Main difficulty in the whole process arises from the natural blind-spots of the decision making points. Questions regarding the possibility of getting pregnant to minimise the risk of having an affected baby, requires an hand-in-hand approach with medicine and genetics. Thanks to the advancements in carrier screening, reproductive technologies, preimplantation testing and prenatal testing, this process now can be conducted with minimal stress and more reliable information to build decisions upon.

The aim of this event is to provide a medium to bring together parental candidates with RD, or with family history of RDs, academicians, health care professionals, representatives from government agencies, reproductive health, genetic testing and diagnostics industry representatives, policy makers, reimbursement authorities, NGOs and PAOs in order to raise awareness on the scientific and clinical state of the art, learning from real life experiences and creating networking opportunity for all counterparts. The event will be held in İstanbul/ Türkiye and live, online participation option is available.

Round 10 (Collection date March 2023)

Applicants

Country

Wolf, Nicole (Principal applicant)

Dept. Child Neurology, Amsterdam Leukodystrophy Center, Amsterdam University Medical Centers

The Netherlands

Mochel, Fanny

Dept. Genetics, Groupe Hospitalier Pitié-Salpêtrière, Paris

France

Groeschel, Samuel

Dept. Child Neurology, University Children’s Hospital Tuebingen

Germany

Zerem, Ayelet

Pediatric Neurology Institute, Dana-Dwek Children’s Hospital, Tel Aviv Sourasky Medical Center & Sackler Faulty of Medicine, Tel Aviv University

Israel

Fumagalli, Francesca

Pediatric Immuno-hematology Unit –Neurology Unit, San Raffaele Hospital, Milan

Italy

Abstract
Metachromatic Leukodystrophy (MLD) experts from the MLD initiative (MLDi) and the European MLD guideline working group organize a face-to-face meeting to accelerate MLDi registry-based studies and guideline development. It will be a two-day meeting in September 2023 in Amsterdam. With emerging new treatments, new clinical, research and regulatory questions arise. Studies based on the MLDi registry can help answering those questions. A clinical guideline is necessary to reach consensus on the best disease management. The above-mentioned groups of experts regularly meet digitally. A face-to-face meeting with dedicated time to work together will be beneficial for speeding up the projects. In the meeting we aim to reach consensus on the remaining open issues in the clinical guideline. Besides that, designs and project plans for MLDi-registrybased studies will be established

Applicants

Country

Sireau, Nick (Principal applicant)

The AKU Society, Cambridge

United Kingdom

Prent, Annelies

Tyrosinaemia Foundation, Nietap

The Netherlands

Teke Kısa, Pelin

Dept. Paediatrics, Division of InbornErrors of Metabolism, University of Izmir Health Sciences and Paediatric Surgery and Research Hospital, Izmir

Türkiye

Lakshminarayan, Ranganath

Clinical Biochemistry & Metabolic Medicine, Royal Liverpool Hospital, Liverpool University Hospitals

United Kingdom

Hughes, Juliette

Medical School, Faculty of Health, Social Care and Medicine. Edge Hill University, Ormskirk

United Kingdom

Fabian, Peter

Dept. Experimental Biology, Masaryk University, Brno

Czech Republic

Zatkova, Andrea

Institute for Clinical and Translational Research, Biomedical Research Centre of the Slovak Academy of Sciences.

Slovakia

Van Spronsen, Francjan

Dept. Metabolic Diseases, University of Groningen Medical Centre

The Netherlands

Van Ginkel, Wiggert

Dept.Paediatrics – Section Metabolic Diseases University of Groningen, University Medical Centre Groningen

The Netherlands

Abstract
The inherited disorders of metabolism alkaptonuria (AKU) and hereditary tyrosinaemia type-1 (HT-1) are devastating conditions. AKU is a slowly progressive disease that leads to a crippling disability and chronic pain. Untreated, HT-1 is a fatal disease that causes liver failure and kidney problems. AKU affects an estimated one in every 250,000 people, while HT-1 is estimated to affect one in every 100,000 people. These conditions are treated with a drug called nitisinone, which has had a life-changing impact on both patient groups. Nitisinone treatment, although highly effective, leads to a condition known as hypertyrosinaemia which can cause blindness, severe skin rashes, and brain damage in children if a strictly controlled diet is not followed.

This conference will have a highly specialised focus on treating nitisinoneinduced hypertyrosinaemia in AKU and HT-1. Together, the AKU and HT-1 patient groups will unite their respective scientific communities to share their research into hypertyrosinaemia and plan and coordinate scientific studies into developing potential treatments.

This event will be hosted in Slovakia by the AKU and HT-1 patient groups. Slovakia is a world-leading hub for research into these conditions, while it also has a significantly higher AKU prevalence, with one in every 19,000 people being affected by the condition, making the aims of this event particularly relevant to AKU patients and researchers in Slovakia.

Applicants

Country

Cazzagon, Nora (Principal applicant)

Dept. Surgery, Oncology and Gastroenterology, University of Padova

Italy

Bergquist, Annika

Upper GI disease, hepatology unit, Karolinska University Hospital, Stockholm

Sweden

Ytting, Henriette

Gastrounit, Dept. of Medical Gastroenterology and Hepatology, Hvidovre University Hospital, Copenhagen

Denmark

Papp, Maria

Institute of Gastroenterology, University of Debrecen, Clinical Center

Hungary

Schramm, Christoph

Dept. Medicine, University Medical Center Hamburg-Eppendorf

Germany

Hoogwater, Frederik

Dept. Surgery, Division of HPB Surgery and Liver Transplantation, University Medical Center Groningen

The Netherlands

Walmsley, Martine

PSC support, Manchester

United Kingdom

Abstract
Primary sclerosing cholangitis (PSC) is a rare and complex disease of the bile ducts that can lead to liver failure. There is no effective medical treatment for PSC, and liver transplantation is the only life-saving treatment option for some patients. Most people with PSC also have another disease called inflammatory bowel disease (IBD). We don’t know why, but IBD disease activity (such as the parts of the colon affected and severity) is different in people with PSC compared to those without PSC, so much so that it is referred to as PSC-IBD.

Sadly, people with PSC-IBD have a higher risk of colorectal cancer (CRC) than not only the general population but also people who have IBD alone. We cannot predict who will get CRC, or exactly how PSC-IBD affects PSC and vice versa, particularly after liver transplantation and colon surgery. This means that every year, all patients with PSC-IBD must have an invasive procedure called colonoscopy to check for signs of cancer.

We will bring in Padova, in 2023, experts together from many disciplines (including patients) to find the best way to understand the relationship between PSC-IBD and PSC, identify who is at highest risk of CRC and the best treatments for PSC-IBD. This knowledge will help us develop a personalised treatment and cancer screening programme where the lowest risk PSC-IBD patients will have fewer colonoscopies and the highest risk will have them more often. This will provide reassurance for PSC-IBD patients that they are being screened effectively and will lead to more efficient use of resources on healthcare systems.

Applicants

Country

De Graaf, Petra (Principal applicant)

Dept. Urology, University Medical Center Utrecht

The Netherlands

Frankiewicz, Mikołaj

Dept. Urology, Medical University of Gdańsk

Poland

Olsen Ekerhult, Teresa

Dept. Urology, Sahlgrenska University Hospital, Institute of Clinical Sciences, Götenborg

Sweden

Abstract
A congenital disease is for life. Even though most congenital diseases are not life threatening, the patient is born with it and dies with it. Posterior hypospadias is a male-exclusive congenital disease in which the tube to pass urine from the bladder to outside (urethra) is insufficiently developed in the penis. Therefore, the opening or meatus, which is normally at the end of the penis, now lies at the base of the penis or even in or underneath the scrotum. Posterior hypospadias can have a large impact on life. Consequences include dissatisfaction about appearance, spraying of the urinary stream, inability to urinate in standing position, and a bent penis in erection.

A multidisciplinary group of specialists, including patient representatives, will meet in this network event to explore what is needed for better counselling and better treatment for hypospadias patients. Surgery for hypospadias remains challenging and no single technique is applicable to all patients. Patients frequently require reoperations. Although transition care from children into adulthood is recommended, follow up of hypospadias patients is lost due to decentralized paediatric and adult health care.

This workshop is aimed to identify what is currently missing in the lifelong treatment of posterior hypospadias, to improve care, quality of life and awareness for these patients. By bringing together clinicians, basic scientists and other specialists in a think tank we expect innovative solutions that will not only help posterior hypospadias but also other urethral diseases.

Applicants

Country

Lindert, Judith (Principal applicant)

Dept. Paediatric Surgery – Colorectal Center, University Hospital Rostock

Germany

Golebiewski, Andrzej

Dept. Paediatric Surgery, Ernica Center Gdansk, University Hospital Gdansk

Poland

Loukogeorgakis, Stavros

Dept. Paediatric Surgery, Specialist Colorectal Service, Great Ormond Street Hospital, London

United Kingdom

Cavalieri, Duccio

Amorhi- Italian Association of Hirschsprung disease patients, Pisa

Italy

Prini Prato, Alessio

Dept. Paediatric Surgery, Centro Bosio per la Patologia Digestiva Pediatrica, University of Genoa

Italy

Modrzyk, Anna

Children’s Developmental Defects Surgery and Traumatology, Medical University of Silesia, Katowice

Poland

Lemli, Anette

SOMA- Patient Organisation for People with Anorectal Malformations, Hirschsprung’s Disease and Cloacal Exstrophy, München

Germany

Amerstorfer, Eva

Universitätsklinik für Kinder- und Jugendchirurgie, Graz

Austria

Davidson, Joseph

Great Ormond Street Institute of Child Health, University College London

United Kingdom

Märzheuser, Stefanie

Dept. Paediatric Surgery – Colorectal Center, University Hospital Rostock

Germany

Abstract
First Paneuropean Network event on holistic care for Hirschsprung Disease and Total Colonic Agangliosis, a joint collaboration between Poland, UK, Italy, Austria and Germany, taking place in Warnemünde at the Rostock Colorectal Center. Hirschsprung Disease (HSCR) is a rare disease affecting the capability to pass stool and results in obstruction of the bowel. Babies may present in the neonatal period with nonspecific symptoms, but also later in childhood. This condition can be life threatening if not treated, and there are ongoing effects of the condition that continue, even after corrective surgery. Furthermore it is crucial to arrange good follow up to adult service (transition) once the child becomes an adult.

To provide the best possible outcome, a lifelong dedicated treatment by a multidisciplinary team is needed. Bowel continence and constipation may persist despite optimal surgical management, in such patients, daily bowel management and surrounding support can enable social continence and mitigate the associated impact on quality of life. Patient Associations and Parent Support Groups can play a crucial role to support families and work together with clinicians. As HSCR is a rare disease, holistic pathways of care and clinical support would enable care providers to offer the best treatment possible to patients.

 

Applicants

Country

Westerheim, Ingunn (Principal applicant)

Osteogenesis Imperfecta Federation Europe (OIFE), Mechelen

Belgium

Micha, Dimitra

Dept. Human Genetics, Amsterdam UMC

The Netherlands

Zhytnik, Lidiia

Dept. Traumatology and Orthopeadics, Tartu University

Estonia

Anticevic, Darko

Dept. Orthopaedics, Speciality Hospital « St. Catherine » & J.J.

Strossmayer, University of Osijek, Zagreb

Croatia

Eekhoff, Marelise

Dept. Internal Medicine section Endocrinology, Amsterdam UMC

The Netherlands

Liepina, Dace

Latvijas Osteogenesis Imperfecta Biedrība (LOIB), Riga

Latvia

Åström, Eva

Dept. Neuropediatrics, Astrid Lindgrens Childrens Hospital, Stockholm

Sweden

Munoz, Ruben

Psychology Service, Fundacion Ahuce (Spanish Osteogenesis Imperfecta Foundation), Valencia

Spain

Wekre, Lena Lande

TRS National Resource Center for Rare Disorders, Sunnaas Rehabilitation Hospital, Nesodden

Norway

Abstract
Under the title « Balancing life with OI” we aim to organize a topical meeting about pain in osteogenesis imperfecta (OI) in relation to its effect on QOL determinants such as fatigue, sleep, work/life balance, health and family relationships. The meeting will take place in Stockholm, Sweden from June 9 to 10th 2023. We expect ca 150 participants from Europe and beyond. The programme will consist of a mix of longer talks from invited speakers, shorter talks based on abstracts, workshops, panel discussions and poster presentations.

Lack of understanding and poor management of pain in the OI field is severely impacting the QOL of OI patients. Addressing this gap is the rationale for this networking event aiming for the first time to bring together all stakeholders on this subject. The meeting will offer arenas to present state of the art research, treatment methods and very importantly the patient perspective.

Our goal is to create new networks between researchers and clinicians to optimally fulfill patient needs. We believe that multidisciplinary attendance from the OI-community will accurately help to identify the most important shortcomings in the pain OI field which will stimulate research towards innovative solutions.

This is the first time that an international conference will be organized exclusively on the topic of pain in OI. We believe that the event is highly feasible considering that OIFE already has experience with successfully organizing 4 topical meetings in addition to other larger OI-related events.

Applicants

Country

Hansikova, Hana (Principal applicant)

Dept. Paediatrics and Inherited Metabolic Disorders, Charles University, The First Faculty of Medicine, Prague

Czech Republic

Bommer, Guido

De Duve Institute – Biochemistry, UCLouvain, Woluwe St. Lambert

Belgium

Thiel, Christian

Centre for Child and Adolescent Medicine, section Glycosylation deficiencies, University of Heidelberg

Germany

Foulquier, Francois

CNRS UMR 8576, Structural and Functional Glycobiology unit, Lille University

France

Taverna, Elena

Neurogenomics Centre, Human Technopole, Milan

Italy

Videira, Paula

CDG&Allies, Glycoimmunology Group, UCIBIO, Faculty of Sciences and Technology of Nova University of Lisbon

Portugal

Matthijs, Gert

Center for Human Genetics, KU Leuven

Belgium

Kornak, Uwe

Institute of Human Genetics, University Medical Center Göttingen

Germany

Lefeber, Dirk

Dept. Neurology, Translational Metabolic Laboratory, Radboud University Medical Center, Nijmegen

The Netherlands

Ferreira, Vanessa

Portuguese Association for CDG, Aroeira

Portugal

Abstract
Congenital Disorders of Glycosylation (CDG) are a group of >160 different rare inborn errors of metabolism. Individuals present with extremely variable and complex clinical symptoms including, but not limited to, developmental delay, multi-organ involvement, neurologic symptoms and dysmorphic features. This makes diagnosis of CDG very difficult.

Over the past 2 decades, members of the EUROGLYCAN network have established considerable clinical and fundamental research expertise on CDG. Effective multidisciplinary collaboration and communication is critical to further our understanding of CDG and, eventually, develop new therapies.

We wish to organize a networking meeting in Prague, Czech Republic in June 2023. The specific goals are:

  1. i) Ensuring the continuation of long-standing collaborations while at the same time, integrating new research teams into EUROGLYCAN.
  2. ii) Promoting the creation of clinical reference centres in more countries and integrate their clinicians into the working group on CDG of MetabERN.

iii) Strengthening the collaboration between the CDG patient advocacy organisations and EUROGLYCAN’s clinical and research network.

  1. iv) Preparing A New Generation of experts in CDG research and clinics.

This will be the first meeting of a fledgling group of PhD students and postdocs: ‘Young CDG’. The initiative will allow these young researchers to organize training courses, help PAOs and clinicians to raise awareness of CDG both inside and outside the academic community, and to join forces with WCDGO for the organization of the 2025 World CDG conference.

 

Applicants

Country

Sauvestre, Angélique (Principal applicant)

DEBRA France, Marseille

France

Hickey, Sinead

DEBRA Ireland, Dublin

Ireland

Hussain, Sagair

DEBRA UK, Berkshire

United Kingdom

Sendin, Gaston

DEBRA Austria, Vienna

Austria

Tarrats, Núria

DEBRA Spain, Marbella, Málaga

Spain

Bolling, Marieke

Dept. Dermatology, University Medical Center Groningen

The Netherlands

Korte, Eva

Dept. Dermatology, University Medical Center Groningen

The Netherlands

Abstract
Epidermolysis bullosa (EB) is group of rare genetic skin fragility conditions characterized by blistering, wounds, and dependent on the type of EB scarring, deformities, mucosal and extracutaneous involvement with currently no approved treatment available to patients in daily practice. Treatment is now aimed at wound care and symptomatic treatment (pain, itch, infection, etc). Today there are many difficulties in developing treatments for EB. We proposed to bring stakeholders together to discuss and address the challenges faced in developing treatments for EB. Two of the biggest challenges are the lack of harmonisation of outcomes to evaluate the different studies that are being realized in EB and the lack of access to centralised registries to make EB treatment development more efficient. We aim to organize the first international consensus workshop to focus on these key challenges to connect and unite the stakeholders involved in EB research, including EB experts, clinicians, trialists, patient representatives, pharmaceutical companies, funding agencies and regulatory agencies. The results will be creating important relationships between stakeholder to overcome these obstacles and the publication of recommendations from the stakeholders that DEBRA International can use in advocacy to overcome these challenges.

Applicants

Country

Schultze Kool, Leo (Principal applicant)

Dept. Radiology, Radboud University Medical Center, Nijmegen

The Netherlands

Vikkula, Miikka

Dept. Human genetics, de Duve Institut, Brussels

Belgium

Kapp, Friedrich

Dept Pediatric Hematology and Oncology, Medical Center – University of Freiburg

Germany

Abstract
VASCERN is the ERN on Rare Multisystemic Vascular Diseases. VASCA is one of the 6 working groups of VASCERN, dedicated to the treatment of patients with vascular anomalies. Vascular anomalies are a large group of vessel diseases characterized by an abnormal vessel formation. VASCA is formed by 14 expertise centers, as well as 3 recently identified potential centers from underrepresented countries (Poland, Rumania, Czech Republic). Each expertise center has an extensive multidisciplinary team of Surgery, Interventional Radiology, Internal Medicine, Dermatology and Genetics. Depending on the type of the vascular anomaly, a different treatment is used, including laser, medical treatment, sclerotherapy, embolization and surgical resections. These treatments are often sequential and can take years to complete, so there is an urgent need for developing new therapeutic options for patients. In this regard, collaboration between experts from different disciplines is key to improve patient care.

Therefore, VASCA wants to organize a two-day face-to-face meeting in Brussels at the end of August 2023. In contrast to the previous meetings of VASCA, that took place within VASCERN, this event would allow the presence a higher number of participants, including different disciplines from the different centers. Also, a greater presence of patient representatives, allowing exchange of ideas and targeting of areas for care improvement. This would favor closer collaborations, knowledge exchange and the possibility to start research projects at the level of the different specialties.

Applicants

Country

Gross, Catharina (Principal applicant)

Dept. Neurology with Institute for Translational Neurology, University (WWU) and University Hospital (UKM) of Münster

Germany

Willekens, Barbara

Dept. Neurology, Antwerp University Hospital

Belgium

Bauer, Jan

Dept. Neuroimmunology, Center for Brain Research, Medical University of Vienna

Austria

Kleffner, Ilka

Dept. Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum

Germany

Laureys, Guy

Dept. Neurology, University of Ghent

Belgium

Liblau, Roland

Dept Neuroimmunology, Toulouse Institute for infectious and inflammatory diseases (Infinity), University of Toulouse III, Toulouse University Hospital

France

Papo, Thomas

Dept. Internal Medicine, Hospital Bichat, University of Paris

France

Schoeters, Eva

RaDiOrg, Organisation of Rare Diseases Belgium, Brussels

Belgium

Wiendl, Heinz

Dept. Neurology with Institute of Translational Neurology, University (WWU) and University Hospital (UKM) of Münster

Germany

Wokke, Beatrijs

Dept. Neurology, MS Centre ErasMS, Rotterdam

The Netherlands

Abstract
Susac syndrome (SuS) is a rare autoimmune disease affecting the brain, retina, and inner ear resulting in a diversity of symptoms including cognitive impairments, visual and hearing loss. Diagnosis SuS is hampered by the heterogeneity of symptoms in early disease stages and lack of awareness among clinicians. Due to lack of clinical trials and high-quality longitudinal data from patient registries treatment paradigms are only based on expert opinions. Therefore, we will bring together a dedicated group of established scientists and clinical experts as well as young investigators.

We aim to establish an international research community to improve our understanding of SuS for the patients’ benefit. Our objectives are to exchange current knowledge and address knowledge gaps on

(i) causes and pathophysiology of the disease,

(ii) improvement of diagnosis and prognosis, and

(iii) treatment options.

This event will serve as a starting point to set up an international SuS consortium (I-SuSaC), thereby laying the groundwork for future scientific collaborations and joint applications. This meeting will result in a consensus agreement on harmonization of a clinical data repository combined with standardized sample processing for a joined SuS biobank. The voice of the patients will be represented by a patient report and a representative from RaDiOrg (https://radiorg.be) as so far there is no official patient organization dedicated to SuS. To guarantee excellent interaction, we plan to organize a face-to-face meeting on June 15th and 16th 2023 at the University Hospital of Münster, Germany.

Applicants

Country

Loeys, Bart (Principal applicant)

Center of Medical Genetics, University of Antwerp

Belgium

Laufer, Andrea

Dept. Children’s Orthopedics, Deformity Reconstruction and Foot Surgery, University Hospital Muenster

Germany

Krebsová Alice,

Dept. Cardiology, Center of inherited cardiovascular diseases, IKEM (Institute of Clinical and Experimental Medicine), Prague

Czech Republic

Pitcher, Alex

Dept. Cardiology, Oxford University Hospitals NHS Trust

United KIngdom

van de Laar, Ingrid

Dept. Clinical Genetics, Erasmus University Medical Center, Rotterdam

The Netherlands

Wijnands, Inka

PAO Contactgroup Marfan and related disorders . Nijkerk

The Netherlands

Verstraeten, Aline

Center of Medical Genetics, University of Antwerp

Belgium

Abstract
In the field of rare diseases the perfect harmony of research is driven by and for patients. For this purpose, we organize a combined face-to-face patient and research conference: the first European Loeys-Dietz syndrome patient and research networking conference. On day 1, 24th of June 2023, we will focus on education of patients and health care professionals. The format consists of lectures by key experts in the different medical aspects of Loeys-Dietz syndrome and break out sessions on specific patient focussed issues. In these small and low barrier groups, patients and experts can ask questions and exchange freely on the topics that worry them in daily life. These include aortic surgery, LDS in children, pregnancy, exercise, nutritional issues and psychosocial challenges and coping strategies. On the second day, 25th of June 2023, we will set the research agenda for next decade on the Loeys-Dietz syndrome. This scientific meeting where state-of-the-art research will be shared in a world café format. Six parallel working groups will focus on specific research domains by sharing expertise, defining current insights and identifying knowledge gaps. By unravelling the exact pathomechanisms, sharing clinical data we aim at finding better treatment strategies and management for LDS patients. To be easy accessible to both patients and scientists the conference will be held at Grauwzusters and Hof Van Liere in Antwerp. A perfect meeting space within our University of Antwerp which can be easily reached public transport (nearby Antwerp Central Station) and, if necessary, by car.

Applicants

Country

Geissler, Jan (Principal applicant)

CML Advocates Network, Bern

Switzerland

Copland, Mhairi

School of Cancer Sciences, University of Glasgow

United Kingdom

Čugurović, Jelena

CML Association of Serbia, Belgrade

Serbia

Abstract
Chronic myeloid leukemia (CML) is a hematological cancer that has become a chronic disease for most patients thanks to the current treatments Tyrosine Kinase Inhibitors-TKIs. Around 65% of patients on TKIs achieve a deep remission of MR4. After years of MR4, patients can try what it is called Treatment Free Remission-TFR, in which no further therapy is required. About 50% of patients relapse after stopping therapy, so successful TFR is only feasible for one third of patients, all others need to be treated life-long. There are still unmet needs, either related to access to therapies and monitoring, or to the side effects burden of a life-long therapy. Hence, finding a cure for CML has become one of the strategic priorities of the CML Community Advisory Board, a working group of the CML Advocates Network, the global network of CML patient groups in 93 countries.

The CML Advocates will hold a meeting that brings together world-leading patient advocates, researchers, and clinicians to jointly explore the barriers and opportunities of research towards new pathways to cure CML. The global patient community will get to expose their current needs and the scientific community will show their current advances. This meeting may be the building block to initiate a “Research Network for CML cure” to help create a joint strategy and milestones to coordinate and fund research towards a CML cure. The face-to-face meeting will encourage new research collaborations, patient involvement in cutting edge science, and a cooperation platform between the patient and scientific CML community.

Applicants

Country

Coutinho, Jonathan J (Principal applicant)

Dept. Neurology, Amsterdam UMC

The Netherlands

Aguiar de Sousa, Diana

Institute of Anatomy, Faculdade de Medicina, Universidade de Lisboa

Portugal

Arnold, Marcel

Dept. Neurology, University Hospital Bern, University of Bern

Switzerland

Putaala, Jukka

Dept. Neurology. Helsinki University Hospital

Finland

Jood, Katarina

Dept. Clinical Neuroscience, Sahlgrenska Academy, University of Gothenburg

Sweden

Van de Munckhof, Anita

Dept. Neurology, Amsterdam UMC

The Netherlands

Abstract
The international research summit on cerebral venous thrombosis is a smallscale research meeting. Cerebral venous thrombosis (CVT) is a rare type of stroke. CVT is caused by a blockage of a vein (a sinus) in the brain. Veins are blood vessels that drain oxygen-poor blood from the organs to the heart and lungs. Because of the blockage of the vein in the brain, the drainage of blood  is disturbed. CVT mostly affects patients aged 20 to 50 years. A severe headache is the most common – and usually first – complaint. In addition, CVT can also cause loss of bodily functions (such as paralysis of an arm and/or leg or speech difficulties) and epileptic seizures. Further research is necessary to better diagnose and treat patients with CVT.

During the two-day international research summit on cerebral venous thrombosis 2023, a group of around 40 experts in the field, together with patients and funding organizations, will discuss where research on CVT should focus on in the coming decade. This will lead to a research agenda that will unite those involved in CVT research from all over the world.

The research summit will take place in Amsterdam (The Netherlands) on June 1-2, 2023 and will consist of multiple sessions in which different themes, such as diagnostic tests or treatment, will be addressed. These sessions will lead to concrete research plans, which then form the research agenda. We also aim to include patients with CVT and media to strengthen the public support of the research agenda.

Applicants

Country

Hedley, Victoria (Principal applicant)

John Walton Muscular Dystrophy Research Centre, Newcastle University

United Kingdom

Charron, Philippe

Centre de référence pour les maladies cardiaques héréditaires, Assistance Publique – Hôpitaux de Paris

France

Lohse, Ansgar

Dept. Medicine, University Medical Center Hamburg-Eppendorf

Germany

Arzimanoglou, Alexis

Service d’epileptologie clinique, des troubles du sommeil et de neurologie fonctionnelle de l’enfant, Hospices Civils de Lyon

France

Straub, Volker

John Walton Muscular Dystrophy Research Centre, Newcastle University

United Kingdom

Lee, Joanne

John Walton Muscular Dystrophy Research Centre, Newcastle University

United Kingdom

Abstract
In 2021, an EJP RD European Reference Network (ERN) training workshop was held to introduce the Advisory Committee for Therapeutics (ACT) model to ERNs. An ACT can help to bridge the gap between promising preclinical data and successful clinical trials, by providing independent and objective expert advice to academia and industry. The model has been successfully deployed in the neuromuscular field for over 10 years but it is readily transferable to other rare diseases, which share similar challenges in drug development. Given the large number of rare diseases (6-8000), strategic oversight in developing ACTs would be beneficial. The thematic groupings which the ERNs are based provide a logical framework for establishing ACTs in other rare diseases.

After this workshop, ERN GUARD-Heart (the ERN focussed on rare and complex diseases of the heart), ERN EpiCARE (the ERN focussed on rare and complex epilepsies) and ERN RARE-LIVER (the ERN focussed on rare and complex diseases of the liver) expressed particular interest in developing their own ACTs. This networking event will give these ERNs a forum to take those next steps by assessing the ACT model with key stakeholders in their fields, including patient representatives. It will enable them to create their core committees and develop plans to launch and sustain an ACT, together with pharmaceutical industry representatives (whose support and understanding of the model is crucial, as they will likely be the main users of this service). The objective is that these ERNs will feel empowered to take the next steps to form their ACTs.

 

Applicants

Country

Simonini, Gabriele (Principal applicant)

Rheumatology Division, Meyer Children’s Hospital, Florence

Italy

Ramanan, Athimalaipet

Dept. Paediatric Rheumatology, Bristol Royal Hospital for Children

United Kingdom

Foeldvari, Ivan

Hamburger Zentrum Kinder- Jugendrheumatologie

Germany

Avcin, Tadej

Dept. Allergology, Rheumatology and Clinical Immunology, Children’s Hospital, University Medical Center Ljubljana

Slovenia

Antòn Lopez, Jordi

Dept. Pediatrc rheumatology, Hospital Sant Joan de Déu, Esplugues de Llobregat (Barcelona)

Spain

Abstract
Chronic non-infectious uveitis of childhood, even though rare, is a severe inflammatory disease that is burdened by sight-threatening complications if not properly recognize and treat. Recently some genetic conditions have been identified as cause of this disease, and a more appropriate treatment has been attempted. The 1st PReS ACADEMY COURSE on Non-Infectious Childhood Chronic Uveitis will be held in Florence (Italy) and will offer access to the latest research, clinical care and treatment related to this disorder. Paediatric rheumatologists and paediatricians will be invited across the world thanks to the valuable help of PReS. The program will be draw by expert from around the world with different expertise, to discuss basic research, advances in clinical practice, novel therapeutic options and novel genetics findings.

This unique networking event is ideal to improve the care and outcome of patients affected by this condition and to foster the achievement of a uniform standard of care across different countries in Europe. Our key speakers are leading experts in translational science (S Angeles-Han), novel therapeutic options (AV Ramanan) and autoinflammatory disease with uveitis (C Rosè, C Wouters). The ophthalmologist point of view will be given by several experts in this field, pointed out that a close collaboration between them and pediatric rheumatologist is crucial for the best management of these patients. Additionally, the point of view and experience of early career scientists will be presented in order to stimulate the discussion among experts.

Applicants

Country

Malfait, Fransiska (Principal applicant)

Center for Medical Genetics, Ghent University Hospital

Belgium

Szekanecz, Zoltán

Dept. Rheumatology, University of Debrecen

Hungary

Castori, Marco

Division of Medical genetics, Foundation IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo

Italy

Bénistan, Karelle

Center for Medical Genetics, Hôpital Raymond Poincaré, Garches

France

Ferraris, Alessandro

Center for Medical Genetics, San Camillo Forlanini Hospital, Rome

Italy

Demirdas, Serwet

Dept. Clinical Genetics, Erasmus MC, Rotterdam

The Netherlands

Bloom, Lara

EDS Society, London

United Kingdom

Frank, Michael

Centre National de Référence des Maladies Vasculaires Rares, AP-HP, Hôpital Européen Georges Pompidou, Paris

France

Abstract
The Ehlers–Danlos syndromes (EDS) are a group of rare heritable connective tissue disorders, hallmarked by joint hypermobility, skin fragility, easy bruising, abnormal wound healing and widespread connective tissue friability. Of concern to this application are the types of EDS in which the underlying genetic causes have been identified (all except hypermobile EDS). These conditions are associated with increased morbidity and mortality, due to complications of tissue fragility, such as vascular and organ ruptures, and musculoskeletal complications. People with these types of EDS types are likely to have problems with diagnosis and lack of information about their condition. These issues decrease quality of care and often subject people to inadequate evaluation.

The hybrid networking event (August 30-31 2023, Ghent, Belgium) aims to bring together scientists, health care providers, patient advocate groups and patients to discuss current knowledge on the genetic and pathophysiological basis of these conditions, classification, and strategies needed to optimize diagnosis, care and treatment. Aim is to strengthen and expand clinical and basic research networks with identification of the most pertinent research questions. The meeting combines state-of-the art presentations, presentations by early career scientists and group discussions. It is linked to a patient-oriented meeting in which the current knowledge on genetically defined EDS types are presented to an international audience including patients and non-specialist clinicians.

Applicants

Country

Eggermann, T. (Principal applicant)

Institute of Human Genetics and Genome Medicine, Medical Faculty, RWTH University Aachen

Germany

Mackay, Deborah

Faculty of Medicine: Human Development & Health, University of Southampton

United Kingdom

Tümer, Zeynep

Dept. Clinical Genetics, Kennedy Center, Copenhagen University Hospital, Rigshospitalet

Denmark

Bliek, Henriette

Dept. Human Genetics, AmsterdamUMC

The Netherlands

Lapunzina, Pablo

INGEMM-Institute of Medical and Molecular Genetics, Hospital Universitario La Paz. Madrid

Spain

Õunap, Katrin

Institute of Clinical Medicine, University of Tartu

Estonia

Riccio, Andrea

Dept. Environmental, Biological and Pharmaceutical Sciences and technologies, Università della Campania Luigi Vanvitelli, Caserta

Italy

Burnyte, Birute

Institute of Biomedical Science, Vilnius University

Lithuania

Netchine, Irène

Explorations Fonctionnelles Endocriniennes-Molecular Endocrinology and Imprintingdisorders molecular diagnosis laboratory, Hôpital Trousseau Children’s hospital, Sorbonne Université, Paris

France

Maher, Eamonn

Dept. Medical Genetics, University of Cambridge

United Kingdom

Abstract
Imprinting disorders (ID) are a group of rare inborn disorders with serious impacts on growth, development, metabolism and behaviour. Early diagnosis enables the targeted management that can transform medical outcome for IDs, but undiagnosed children are at risk of issues such as obesity, diabetes, developmental problems, and in some cases childhood cancer; these issues have severe consequences for patients and their caregivers.

The textbook view of IDs is that each one involves a different set of genes; but in recent years our group have discovered that about a quarter of affected children have a so-called multi-locus imprinting disturbance (MLID) – that is, two or more sets of genes are affected at once. As MLID is recognised in more children, we learn more about its causes and effects. But patients, families and healthcare professionals urgently need standardised guidelines on what MLID is, when and how to look for it, how to diagnose it, how it affects patients, and how to manage it.

We will meet this need by holding an international network event to develop guidelines that are acceptable across the ethical, legal, social and medical systems of different nations. We will take fundamental insights from research and translate them into direct impact on patient care. Our work will be invaluable for healthcare professionals, making them more familiar with MLID in the wider context of IDs, and for patients and families, enabling them to secure the clinical and molecular diagnosis through which they will access personalised management.

Applicants

Country

Karatzias, Vasileios (Principal applicant)

Hellenic Friedreic’s Ataxia Association, Thessaloniki

Greece

Millman, Sue

Euro-ataxia, London

United Kingdom

Giunti, Paola

Dept Molecular Neuroscience, UCL, London

United Kingdom

Chatzistergos, Konstantinos

Laboratory of developmental biology, Aristotle University of Thessaloniki, School of Biology

Greece

Schmeder, Madeleine

Association Française Ataxie de Friedreich, Hirson

France

Gerbild, John

Ataxia Denmark, Ølstykke

Denmark

Nadke, Andreas

German Heredo Ataxia Society, Stuttgart

Germany

Abstract
Ataxias are a group of rare neurological disorders that affect balance, coordination, and speech. There are many different causes of ataxia. Many ataxias are inherited conditions caused by defects in certain genes. The most common inherited progressive ataxia is Friedreich’s ataxia. Research is ongoing to identify other genes which cause inherited cerebellar ataxias and discover how they exert their effects. However, there are still many patients who do not have a specific diagnosis for their inherited ataxia. Despite recent research advancements, many forms of Ataxia have no treatment.

Multistakeholder collaboration is key to advancing research. Combing expertise of stakeholders in the field of Ataxia around Europe is of high importance to bridge the gap between scarce research and therapy development. The goal of the European Ataxia Conference is to present new therapeutic approaches and research results to the patients through the patient groups, and the scientific community.This networking event will provide patients with the opportunity to ask questions and understand the future of research and medical advances in Ataxias. The new research on gene discovery, and development in diagnosis, emerging and existing therapeutics, natural history, and biomarkers, will be presented and discussed.

This 2-day event includes presentations, networking, and Q&A sessions to promote exchange and knowledge sharing. This event will expand the Euroataxia network and offer a unique educational opportunity for all the participants.

Applicants

Country

Evangelista, Teresinha (Principal applicant)

Direction de la Recherche Clinique et de l’Innovation (DRCI), ERN EURO-NMD, Assistance Publique – Hôpitaux de Paris

France

Mancuso, Michelangelo

Dept. Clinical and Experimental Medicine, Neurological Institute, University of Pisa

Italy

Kornblum, Cornelia

Dept. Neurology, Neuromuscular Diseases Section, University Hospital Bonn

Germany

Molnar. Maria Judit

Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest

Hungary

Abstract
Endorsed by the European Reference Networks EURO-NMD, RND, EpiCare, MetabERN and EYE, the interERN mitochondrial working group aims to develop a consensus on care and safe medication use in patients with epilepsy caused by a primary mitochondrial disease. This consensus will help to develop expert state-of-the-art knowledge for patient management.

Primary mitochondrial diseases are inborn errors of energy metabolism, with a combined prevalence of 1/5000. Typically affect tissues with high-energy requirements, including the brain. Epilepsy is one of the main neurological manifestations, occurring in up to 60% of patients. Seizures are often resistant to medication and may develop into refractory non-convulsive status epilepticus, where the non-convulsive electric activity of the brain does not respond to adequate initial therapy. The major genetic causes of mitochondrial epilepsy are mutations in mitochondrial DNA and in the nuclear encoded-gene POLG. Treatment of mitochondrial epilepsy is challenging even for expert epileptologists. Examples of this difficulty are the risk of valproate toxicity and propofol infusion syndrome. Reason why standards of care need to be developed and disseminated.

A panel of experts in mitochondrial medicine, representative of the five ERNs will meet in June 2023 in Paris. During this workshop, the experts will produce a consensus paper on the management of epilepsy in mitochondrial diseases. Its dissemination and a plan for updating and curating the consensus paper will also be established.

Applicants

Country

Schimmel, Joost (Principal applicant)

Stichting IJzersterk, Wieringerwerf

The Netherlands

Wise, Rachel

Dept. Metabolic Biochemistry, Ludwig Maximilian University of Munich

Germany

Papandreou, Apostolos

Dept. Molecular Neurosciences, Great Ormond Street Institute of Child Health, University College London

United Kingdom

Mauthe, Mario

Dept. Biomedical Sciences of Cells & Systems, University Medical Center Groningen

The Netherlands

Synofzik, Matthis

Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Brain Research & Center for

Neurology, Tübingen

Germany

Nielbock, Markus

Hoffnungsbaum e.V., Heidelberg

Germany

Cappa, Silvia

AISNAF, MIlan

Italy

Coste, Dany

Autour du BPAN, Ouches

France

Mollet, Fatemeh

NBIA Suisse, Lausanne

Switzerland

Botezán, Ovidiu

NBIA Hungary, Magyarországi Mitochondrialis

Betegek Alapítványa, Budapest

Hungary

Abstract
Beta-propeller Protein-associated Neurodegeneration (BPAN) is a severe rare disease affecting 2-3 per million individuals. Children with BPAN often suffer from severe developmental delay and epileptic seizures, which later progresses into dementia and parkinsonism. With the causal genetic mutation for BPAN only identified in 2012, research on molecular and cellular disease mechanisms is still in its infancy. Consequently, there is no treatment or cure for BPAN at this time. Nevertheless, increased interest in studying BPAN has resulted in novel disease model systems, natural history studies are being performed, novel therapies are being tested, and Patient Advocacy Organisations (PAOs) are working together with the overall aim to improve our understanding of the disease and find an effective treatment or cure.

This network event will be held in October 2023. It will bring together clinicians and academic researchers specialized in BPAN, as well as representatives from PAOs. The major aims of this event are to: i) identify the greatest barriers to basic, translational, and clinical research for BPAN, ii) generate a comprehensive list of currently available resources to include in a centralized, open-access, searchable database, and iii) discuss concrete actions to expand the BPAN research network, incentivize international collaboration, and promote career development of early career scientists. We envision that this network event will pave the way to novel discoveries, and thereby hopefully will accelerate the search for an effective treatment of this devastating disease.

Applicants

Country

Roche Martinez, Ana (Principal applicant)

Dept. Pediatric Neurology, Parc Taulí University Hospital, Sabadell, Barcelona

Spain

Vigevano, Federico

Dept. Pediatric Neurology, Hospedale Bambino Gesu, Rome

Italy

Bindels de Heus, Karen

Dept. Pediatrics, ErasmusMC, Rotterdam

The Netherlands

Ourani, Sofia

Clinical Genetics clinic, Department of Paediatrics, Hospital Archbishop Makarios III. Nicosia

Cyprus

Coritza, Debora

Dept. PediatricNeurology, Parc Taulí University Hospital, Sabadell, Barcelona

Spain

Abstract
Angelman syndrome (AS) is a rare disease consisting of neurodevelopment delay, hypotonia, absent speech and very often epilepsy. It is sometimes difficult to find an expert clinic on AS in some European countries, which may contribute to a delayed diagnosis or clinical management issues. A group of European clinicians working on AS participating in some phase 1 studies for the disease, have decided to share our experience and projects to improve knowledge and create a well stablished net. Now we already have the motivation, it is necessary to stablish an organized structure to be able to meet in the following 12 months, for research moves forward with new molecules and treatments. Choosing a hybrid format is crucial to reach as many professionals and families as possible, including health care. This will allow AS families from different parts of Europe to better access clinical specialized global care and a provide a better chance to participate in new early phase studies.

Applicants

Country

Tanesse Daniel (Principal applicant)

European CMT Federation, Brussels

Belgium

Pernice, Ingolf

HMSN/CMT Group, Deutsche Gesellschaft für Muskelkranke e.V.

(DGM)

Germany

Libany Martine

CMT-France, Saint Alban, Cedex

France

Abstract
“Together against CMT” strives for bringing together European scientists, clinicians, other health professionals and patients advocacy groups. This initiative of the European Charcot-Marie-Tooth Federation (ECMTF), which unites almost all CMT patient organizations across Europe, aims at stimulating and promoting interdisciplinary cooperative research in the interest of CMT patients. It includes organizing access for CMT researchers to health data relevant to their research at the European, if not international level. At the same time, we try to mobilize patients to cooperate more closely with the specialists involved and to contribute (with their data as well as in studies and trials) to broaden the basis for successful research.

The aim of this conference Is to share knowledge and create synergies through innovative ideas with different specialist groups from all over Europe, and so enable all people living with CMT to receive an accurate diagnosis, care, and available therapy as soon as possible.

We are pleased to include health professionals and representatives of non-European patient organizations to learn from their experience and to stimulate cooperation also on a global level.

This conference is meant to initiate a process of structured cooperation of the relevant stakeholders including most distinguished researchers invited to set up the “European CMT Research Association”. It will take place in Paris on 9 and 10 June 2023.

Applicants

Country

Tomassi, Massimiliano (Principal applicant)

Famiglie GNAO1 APS, Rome

Italy

Martinelli, Simone

Dept. Oncology and Molecular Medicine, Italian Institute of Health (Istituto Superiore di Sanità), Rome

Italy

Katanaev, Vladimir

Dept. Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva

Switzerland

Ortigoza Escobar, Juan

Movement Disorder Unit, Dept. Pediatric Neurology, Hospital Sant Joan de Deu, Barcelona

Spain

Malenica, Maša

Dept. Child neurology and epileptology, UHC Sestre milosrdnice, EpiCARE, Zagreb

Croatia

Galosi, Serena

Dept. Human Neuroscience, Sapienza University, Rome

Italy

Broekhuizen, Eva

Stichting GNAO1 NL, Leiden

The Netherlands

Silva, Susana

Asociación GNAO1 España, Alcorcón, Madrid

Spain

Jokinen, Julia

GNAO1 Finland, Vantaa

Finland

Abstract
GNAO1 (G Protein Subunit Alpha O1) is a protein coding gene. Most patients with a GNAO1 neurodevelopmental disorder are diagnosed as infants or young children. Many of the patients begin experiencing seizures, abnormal movements and developmental delays in their infancy. The first GNAO1 patients were only identified in 2013. Because of that, the scientific community is still beginning to realize the spectrum of symptoms and impacts from mutations in GNAO1.

This networking event will explore recent developments in this field and create opportunities for new collaborations, debate on the development of precision medicine hypotheses and treatment trials to reach more patients across Europe. One of the strengths of this event will be bringing together senior and young academics, as well as patient advocacy organizations, which will enhance and create new ideas on every aspect of approach to this disease. The event will be held in Rome, Italy in June 2023.

The event will be structured in two days:

  • Day 1: Scientific conference with lectures on both clinical aspects of the disease and updates on ongoing research projects. A round table, between clinicians, researchers and PAOs representatives will also be hosted to discuss the next steps to be taken to move the research forward.
  • Day 2: Dedicated to GNAO1 families, that will have the possibility to spend some time together, share information, experiences, recommendations. Activities for both families and kids will be organized.

Applicants

Country

García-Cazorla, Angeles (Principal applicant)

Dept. Neurology, Hospital Sant Joan de Déu, Barcelona

Spain

Mochel, Fanny

Dept. Medical Genetics, La Pitié-Salpêtrière University Hospital, Paris

France

Pons, Roser

First Department of Pediatrics, “Agia Sofia” Children’s Hospital, University of Athens

Greece

Scarpa, Maurizio

Regional Coordinating Centre for Rare Metabolic Diseases, Azienda Sanitaria Universitaria Friuli Centrale, Udine

Italy

Tangeraas, Trine

Dept. Paediatric and Adolescent Medicine, OUH Rikshospitalet, Oslo

Norway

Opladen, Thomas

Division for Child Neurology and Metabolic Medicine, Centre for

Paediatric and Adolescent Medicine, University Hospital Heidelberg,

Germany

Genova, Suzan

Bulgarian Huntington Association (BHA), Sofia

Bulgaria

Badnjarevic, Ivana

Lil’ Brave One (Hrabrisa), Novi Sad

Serbia

Comas, Montse

Syngap1 Spain association, Madrid

Spain

Finglas, Alan

MSD Action Foundation/ SavingDylan.com, Dublin

Ireland

Abstract
More than 500,000 people in the European Union suffer from a rare neurological disease which can sometimes take years to diagnose and for which often no treatment is available. The European Reference Networks (ERNs) comprise doctors and researchers with expertise in rare or low-prevalence diseases. The ERNs involved in rare genetic neurological diseases are specialized in rare epilepsies (Epi-Care), other neurological conditions that lead to difficulties executing movements and limit many other brain functions (RND-ERN), and disorders that affect muscles and nerves (EURO-NMD). Finally, the MetabERN is specialized in rare disorders that disturb the chemistry of the cells. Whereas these networks are mainly based on the most prominent symptom of patients (epilepsy, disorders of movement, muscle and nerve problems), the chemistry of cells, also called metabolism, is almost always disturbed. Our event tries to see these rare neurological disorders through the “metabolic perspective”.

Highly specialized researchers from different countries will show how energy, proteins and lipids are used in the brain, and how small molecules for communication between neurons (neurotransmitters) may be disturbed in different disorders. This new approach may lead to the discovery of new markers to diagnose disorders. In the same way, this may lead to treat rare disorders from a metabolic perspective: with specific diets or treatments that protect lipid and/or protein equilibrium. Doctors, researchers, young researchers, and patient associations will attend this event in July 2023 in Barcelona.